

# Journal Pre-proof

PROBIOTICS AN EMERGING THERAPEUTIC APPROACH TOWARDS  
GUT- BRAIN-AXIS ORIENTED CHRONIC HEALTH ISSUES INDUCED BY  
MICROPLASTICS: A COMPREHENSIVE REVIEW

Ileshita Pan, Suganiya Umapathy

PII: S2405-8440(24)08035-6

DOI: <https://doi.org/10.1016/j.heliyon.2024.e32004>

Reference: HLY 32004

To appear in: *HELIYON*

Received Date: 7 December 2023

Revised Date: 25 May 2024

Accepted Date: 27 May 2024

Please cite this article as: PROBIOTICS AN EMERGING THERAPEUTIC APPROACH TOWARDS  
GUT- BRAIN-AXIS ORIENTED CHRONIC HEALTH ISSUES INDUCED BY MICROPLASTICS: A  
COMPREHENSIVE REVIEW, *HELIYON*, <https://doi.org/10.1016/j.heliyon.2024.e32004>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier Ltd.



1           **PROBIOTICS AN EMERGING THERAPEUTIC APPROACH TOWARDS GUT- BRAIN-AXIS**  
2           **ORIENTED CHRONIC HEALTH ISSUES INDUCED BY MICROPLASTICS: A COMPREHENSIVE**  
3           **REVIEW**

4  
5 **Author Name:** Ieshita Pan\* and Suganiya Umapathy  
6

7 **Address:** Institute of Biotechnology, Department of Medical Biotechnology and Integrative Physiology, Saveetha  
8 School of Engineering, Saveetha Institute of Medical And Technical Sciences, Thandalam, Chennai-602105, Tamil  
9 Nadu, India.  
10

11 **Running Head: PROBIOTICS AND MICROPLASTIC (MP) INDUCED GUT DYSBIOSIS**  
12

13 **\*Correspondence:** [bony.iesk@gmail.com](mailto:bony.iesk@gmail.com); [ieshitapan.sse@saveetha.com](mailto:ieshitapan.sse@saveetha.com)  
14

15 **Highlights**


- 16           • Food ingested MP trigger direct damage to the GI tract causing intestinal dysbiosis, inflammation, ROS,  
17           neurodegeneration, and organelle damage
- 18           • The hydrophobicity and large surface areas of MP allow toxic pollutants to attach to their surfaces and the  
19           entry routes determine the place of accumulation and severity
- 20           • Probiotics regulate the gut-brain, gut-liver, gut-lung, gut-skin, hypothalamic-pituitary-adrenal,  
21           hypothalamic-pituitary-thyroid, and hypothalamic-pituitary-gonadal axis to control dysbiosis.

22  
23 **Keywords:**

24 Microplastics (MPs), Gut Dysbiosis, Intestinal Barrier, ROS, Neurotransmitter, Neurodegeneration, Gut-Brain-Axis,  
25 Probiotics.

26  
27  
28  
29  
30

## 31 GRAPHICAL ABSTRACT



## 33 ABSTRACT

34 Applications for plastic polymers can be found all around the world, often discarded without any prior care,  
35 exacerbating the environmental issue. When large waste materials are released into the environment, they undergo  
36 physical, biological, and photo-degradation processes that break them down into smaller polymer fragments known  
37 as microplastics (MPs). The time it takes for residual plastic to degrade depends on the type of polymer and  
38 environmental factors, with some taking as long as 600 years or more. Due to their small size, microplastics can  
39 contaminate food and enter the human body through food chains and webs, causing gastrointestinal (GI) tract pain  
40 that can range from local to systemic. Microplastics can also acquire hydrophobic organic pollutants and heavy  
41 metals on their surface, due to their large surface area and surface hydrophobicity. The levels of contamination on  
42 the microplastic surface are significantly higher than in the natural environment. The gut-brain axis (GB axis),  
43 through which organisms interact with their environment, regulate nutritional digestion and absorption, intestinal  
44 motility and secretion, complex polysaccharide breakdown, and maintain intestinal integrity, can be altered by  
45 microplastics acting alone or in combination with pollutants. Probiotics have shown significant therapeutic potential  
46 in managing various illnesses mediated by the gut-brain axis. They connect hormonal and biochemical pathways to  
47 promote gut and brain health, making them a promising therapy option for a variety of GB axis-mediated illnesses.  
48 Additionally, taking probiotics with or without food can reduce the production of pro-inflammatory cytokines,  
49 reactive oxygen species (ROS), neuro-inflammation, neurodegeneration, protein folding, and both motor and non-  
50 motor symptoms in individuals with Parkinson's disease. This study provides new insight into microplastic-induced  
51 gut dysbiosis, its associated health risks, and the benefits of using both traditional and next-generation probiotics to  
52 maintain gut homeostasis.

## 53 INTRODUCTION


54 Microplastics (MPs) are a growing societal issue due to their widespread distribution and accumulation  
55 throughout ecosystems[1,2]. MPs are ubiquitous and persistent in a variety of settings due to the large and ongoing  
56 production, usage, and disposal of plastic materials in contemporary civilization[1,3,4]. The low density and high  
57 durability of polymers have led to a steady increase in plastic production since the 1950's [5,6]. Current society is  
58 experiencing a rapid increase in the worldwide population, along with rapid industrialization[7–9], leading to  
59 various social, financial and ecological concerns such as increased energy demand, environmental damage, and  
60 climate change[10–12]. Improper waste disposal and the slow degradation of plastic have made these polymers  
61 abundant resulting in extensive environmental pollution issues [13]. Once in the environment, plastics begin to  
62 degrade and break into smaller pieces through various processes of abiotic and biotic degradations (**Fig.1**) [14–18].  
63 The size of primary or secondary MPs ranges from 0.1  $\mu\text{m}$  to 5 mm[9,19]. The majority of traditional techniques for  
64 recycling MPs involve reintroducing plastic scrap primarily into the processing unit's heating cycle. This is followed  
65 by converting waste into new plastic products by blending it with virgin polymer, which can significantly lower  
66 production costs [20]. Plastic wastes may occasionally undergo chemical or thermochemical alteration to be  
67 recycled in the industrial loop. There are three different ways that MPs can degrade: physically, chemically, and  
68 biologically. Chemical recycling methods like pyrolysis are very common in the industrial world [20–22]. A variety  
69 of enzymes are involved in the biological degradation process [23,24]. The fundamental procedure involves  
70 breaking down polymers into smaller particles, which are then broken down into oligomers, dimers, and monomers.  
71 Microbes assist in the mineralization processes that follow this degradation. Microorganisms absorb monomers  
72 through specific cell transport systems, allowing them to enter catabolic pathways as a source of carbon. Carbon  
73 dioxide and water are the end products of aerobic metabolism in cells, leading to the mineralization of plastic. It is  
74 commonly known that microalgae attach themselves to plastic surfaces in wastewater streams. This attachment  
75 initiates the decomposition of plastic by generating the exopolysaccharide and ligninolytic enzymes. These polymers  
76 generally function as a carbon source, boosting the amount of proteins and carbohydrates in cells and accelerating  
77 growth [25]. Additionally, it was found that pro-oxidative chemicals or pretreatment are not necessary for  
78 *Oscillatoria subbrevis* and *Phormidium lucidum* to cling to and degrade low-density polyethylene surfaces [26].

79 Furthermore, an extensive variety of intracellular and extracellular enzymes originating from fungi possess the  
80 ability to catalyze an extensive array of reactions and degrade petroleum-based polymers. The metabolism of  
81 aliphatic, alicyclic, and aromatic compounds is aided by the oxidation and conjugation events associated with the  
82 cytochrome P450 family enzyme systems, epoxidases, and transferases [27]. According to Shin et al. (2018) they  
83 perform a wide range of reactions, such as epoxidation, sulfoxidation, desulfuration, dehalogenation, and  
84 deamination [28]. For the breakdown of MPs, bacterial consortiums as well as pure cultures can be used.  
85 Comparatively, biological methods were more effective, but their effectiveness is limited to certain types of MPs.  
86 The presence of organic substances in the environment influences the activity of microorganisms involved in MP  
87 degradation[29].The biggest drawback, however, is the incredibly slow rate of disintegration. Therefore, new  
88 inventive methods to enhance the degrading bacterial isolates and optimize the environment are required to speed up  
89 the degradation process.

90 MPs can adsorb a variety of pollutants, such as PAHs, PCBs, heavy metals, pathogens, and more, due to  
91 their small structure, improved hydrophilicity, surface roughness, the existence of a negative charge on their surface,  
92 and the availability of functional groups [30].Subsequently ,hydrophobic, electrostatic, and non-covalent interactions  
93 between contaminants and MPs are intensified [31–33]. The human body can come in contact with MPs through  
94 ingestion of MP-contaminated food, inhalation of MPs present in the air, and dermal contact with these particles,  
95 found in commercial products, textiles, or in dust, leading to health issues [34]. Aquatic organisms, such as  
96 zooplankton [35], sea grass[36], algae [37], copepods[35], mussels [38], crustaceans [39], Echinodermata species  
97 [40] and fishes [41] are among those that can easily consume MPs. The consumption can have various detrimental  
98 effects, including obstructing the alimentary canal [42], disrupting the endocrine system [35], and ultimately  
99 inhibiting body growth and causing death[43]. Phthalates, a chemical found in plastic and ingested through food, can  
100 alter estrogen activity, leading to reproductive, developmental, and structural damage to host organs [44]. Another  
101 food-ingested polymer, polybrominated diphenyl ether, can interfere with reproductive health, hormone signaling,  
102 and neuronal development, resulting in neurotoxicity, carcinogenicity, behavioral abnormalities in humans,  
103 reducedIQ in children, and autism spectrum disorders upon exposure [45]. MPs can act as vectors for transferring  
104 hydrophobic organic compounds from water due to their large surface area and hydrophobic nature. This leads to  
105 pollutants accumulating more rapidly in aquatic organisms, making them more harmful to humans when consumed.  
106 MPs have been found in various fish species consumed by humans, including parrot fish (Scaridae), marine and  
107 freshwater killfish (*Aplocheilusp.*), tuna (*Scombridae*), cutlass fish (*Trichiurus* sp.), swordfish (*Xiphias gladius*),  
108 and croaker fish. MPs have been detected in human saliva [46], placenta [47,48], lungs [49,50], stool [51,52], and  
109 breast milk [53].

110 The gastrointestinal (GI) tract is the primary site of action for the significant health effects of food-intake  
111 plastic particles, directly harming the body on both a local and systemic level (**Fig.1**). The host is negatively  
112 impacted by the increased gut bacterial load and diversity, which alters the host's immunological and metabolic  
113 pathways, leading to inflammation and gut discomfort [54]. It has been reported that gut organisms are involved in  
114 metabolizing proteins and complex carbohydrates, which help protect the host's immune system. They facilitate  
115 cross-talk between gut epithelial cells and immune cells [55]. Additionally, communication via the vagus nerve, the  
116 metabolism of tryptophan and short-chain fatty acids (SCFA), and the growth of neurons all contribute to regulating  
117 the central nervous system. In the GI tract, gut organism-mediated fat digestion, fat absorption, and complex  
118 carbohydrate degradation are essential for maintaining human health. Although the digestion of plastic particles and  
119 their effect on resident microbial colonization of the gut can be studied using *in vitro* and *in vivo* models, the overall  
120 impact of plastic particles on gut microbes is still unclear. Ethical restrictions, study costs, and the complexities of  
121 multi-step human digestion are real barriers to understanding the effect of plastic particles on gut dysbiosis. Through  
122 a static model, endpoint analysis of digestion and step-specific kinetic studies can be monitored [56,57]. However,  
123 dynamic simulators can monitor the effects of contaminated food, heavy metals, and pharmacological compounds in  
124 a computerized GI model and the area of large intestine nanomaterial-induced gut organisms' metabolic  
125 bioconversion [58]. Thus, the lack of physiological information on plastic particle-induced gut dysbiosis represents a

126 research gap that needs to be addressed. In this manuscript, the main objectives are to investigate the harmful effects  
 127 of MPs on the gut as they act as pollutants. Although several degradation processes are available, the existence of  
 128 MPs in the environment creates a lot of problems. MPs can enter the body through food, disrupting gut health and  
 129 the gut-brain axis. Whether acting alone or in combination with other pollutants on their surfaces, MPs can  
 130 compromise the intestinal barrier, alter the microbial population in the gut, and trigger various cascades that result in  
 131 the production of ROS, causing organ damage and neurotoxicity. We present a potential mechanism initiated by  
 132 MPs upon entry, discuss the consequences, and propose a control mechanism using different probiotics based on  
 133 their modes of action.  
 134




135

136 **Fig.1. Schematic Representation of Microplastics (MP) Generation and Their Portals of Entry to Establish**  
 137 **Severe Health Issues in Human**

138 **CELLULAR AND MOLECULAR EVENTS TRIGGERED BY MP**

139 The gut-brain axis (GB axis) is a complex network process that not only helps the organism interact with its  
140 environment but also aids in nutrient digestion and absorption, intestinal motility and secretion, complex  
141 polysaccharide decomposition, and intestinal integrity maintenance. Thus, it connects the central nervous system  
142 (CNS) and the GI tract [59]. This demonstrates that the brain, the main organ responsible for many physiological  
143 processes, and the GI are closely related [60]. However, exposure to different antibiotics and pathogens can alter the  
144 composition of the gut microbiota and lead to dysbiosis, which can adversely affect the host's health [61]. The  
145 autonomic nervous system (ANS), the vagus nerve, and the X cranial nerve form the core of the GB axis. Afferent  
146 fibres send information from the inner organs to the brain, connecting the CNS to the enteric nervous system (ENS).  
147 The vagus nerve detects signals from various stimuli, while the efferent vagal nerve response depends on the gut  
148 environment, host immune system, and metabolism [62,63]. Additionally, the hypothalamic-pituitary-adrenal axis  
149 (HPA axis) can connect the CNS with the gastrointestinal tract [63]. During times of stress, the hypothalamus  
150 releases corticotrophin-releasing hormone, which stimulates the pituitary gland to produce adrenocorticotrophic  
151 hormone (ACTH). This leads to the synthesis of cortisol (or corticosterone in rats), by the adrenal glands, which also  
152 regulate various gastrointestinal functions. Toxic additives found on MP surfaces can penetrate lipid bilayers and  
153 blood-brain barriers, disrupting the normal function of hypothalamic axes like the hypothalamic-pituitary-adrenal  
154 axis (HPA), the hypothalamic-pituitary-thyroid axis (HPT), and the hypothalamic-pituitary-gonadal axis by  
155 interfering with hormone receptors [64].

156 It is already established that organisms from higher trophic levels ingest MPs either by consuming them  
157 directly, mistaking them for prey, or through lower trophic organisms that have already ingested MPs due to their  
158 limited ability to differentiate between plastic and food [65]. Previous studies focused on MP formation and its  
159 potential health risks, but recent studies have highlighted the entry points of MP and their effects on the human body  
160 [66–68]. The accumulation of MPs can lead to long-term adverse effects in the host body, ultimately increasing  
161 morbidity and mortality rates [65,69,70]. According to Celi *et al.* (2017) [71], the symbiotic balance between the  
162 intestinal tract and local microbes without any dysfunction determines the gut health in animals (**Fig.2**). However,  
163 aquatic animals have a more dynamic gut microbial existence compared to terrestrial vertebrates, and they are highly  
164 sensitive to dietary changes [72,73]. Environmental factors [74], such as diet, antibiotic exposure, environmental  
165 toxins, and acute enteric pathogens can affect host-microbial homeostasis, microbial diversity, and load, leading to  
166 gut dysbiosis [65,66,67]. The genetic makeup of the host is one intrinsic factor, but extrinsic factors also play a role.  
167 In the gastrointestinal tract, gut microbial compositions vary for herbivorous, carnivorous, omnivorous, and filter-  
168 feeding fishes. Issues related to gut health due to microbiota are believed to stem from the interactions between  
169 consumed MPs and gut organisms in the colon [78]. Intestinal microorganisms can respond to environmental factors  
170 that trigger host metabolic and immunological changes through a complex and dynamic system (**Table 1**) [79,80].  
171 Therefore, the contribution of gut organisms is crucial for maintaining a healthy gut and should not be ignored  
172 [72,81].



173

174 **Fig.2.Schematic Representation of Gut-BrainAxis.**

175 The cell membrane serves as a barrier to prevent the free movement of molecules from the cell interior to the  
 176 outside and vice versa. This helps to maintain homeostasis by keeping a stable intracellular environment, allowing  
 177 different biochemical reactions to proceed in an organized manner. Cells can absorb MP through passive infiltration,  
 178 endocytosis, phospholipid hydrolysis, or membrane transport mechanisms [82]. Except for endocytosis, all other  
 179 mechanisms can either directly damage the cell membrane or indirectly enhance ROS production, leading to  
 180 damage. Experimental evidence has shown that PE MP, due to its sharp edge or unique shapes, can rupture  
 181 erythrocyte membranes and cause severe hemolysis [83]. Moreover, a significant amount of MP adsorbed on the  
 182 lipid bilayer can reduce the size of the cell membrane, increase membrane tension, decrease membrane density, alter  
 183 fluidity, and compromise membrane integrity [84,85]. Brief exposure to MP can also lead to a sudden rise in  
 184 intracellular ROS levels resulting in membrane damage and lipid peroxidation [86]. PS-MPs can trigger excessive  
 185 ROS-activated  $\text{Ca}^{2+}$  influx in human hepatocytes through store-operated  $\text{Ca}^{2+}$  channels (SOCs). In L02 hepatocytes,



186 calcium overload halts the cell cycle in the S phase and initiates apoptosis (**Fig.3**) [87]. This overview highlights the  
187 molecular initiating events and key molecular events (KEs) caused by micro- and nanoplastics. These include the  
188 generation of free radicals, activation of oxidative stress metabolism, lipid peroxidation, DNA damage, and  
189 initiation of downstream signaling pathways that precede cascades of branching molecular changes potentially  
190 leading to irreversible oxidative damage and exacerbation of inflammatory processes.

191 • **Consequences due to the altered Gut barrier:**

192 a. *Physical barrier:*

193 Exposure to MPs disrupts the intestinal barrier. In *Artemia parthenogenetica* larvae, 10  $\mu\text{m}$  PS-MPs induced  
194 deformation of intestinal epithelial cells [88]. As the concentration of exposed MP increases, the intestinal cells of  
195 earthworms become enlarged and irregular in shape, and the size of the nucleus is altered [89]. To maintain cell  
196 integrity, tight junction proteins must be functional. These proteins include the intercellular junction complex  
197 protein, composed of occludin, claudins, and the ZO family proteins [90]. Only then can the intestinal barrier work  
198 properly. Tight junction proteins, such as Zo-1 and Claudin-1, have slightly lower transcription levels in the colon  
199 and ileum of mice after 6 weeks of exposure to 5  $\mu\text{m}$  MPs at a concentration of 1000 g/L [91].


200 b. *Chemical barrier:*

201 The mucus layer, which acts as a barrier preventing contact between antigens in the intestinal cavity and host  
202 cells, is known as the chemical barrier. The mucus is primarily produced by goblet cells and consists of mucin,  
203 digestive enzymes, antimicrobial peptides, immunoglobulins like IgA, enzymes, and proteins such as lactoferrin  
204 [92,93]. Additionally, these cells release other mucus-like substances such as FCGBP, ZG16, CLCA1, AGR2, and  
205 TFF3 [94,95]. Abnormal mucin expression is directly linked to various diseases. For example, Muc2 deficiency in  
206 ulcerative colitis, impairs the defense mechanism. Conversely, a 14-day exposure to MPs increases intestinal mucus  
207 in marine medaka fish [96,97]. In juvenile guppies, larger MP size enhances secretion from goblet cells [98].  
208 However, in goldfish larvae, PS-MPs disrupt the structure of the intestinal mucosa and submucosal structure [99].  
209 Exposure to polystyrene beads, polystyrene chips, or polypropylene fibres significantly reduces the amount of  
210 mucus in the intestines of zebrafish. Furthermore, PE-MPs and PS-MPs in zebrafish guts cause epithelial shedding,  
211 increased mucus secretion, and a decrease in goblet cells [100]. In mice, mucin secretion decreases at the mRNA  
212 level for genes like Muc1, Muc2, Muc3, Klf4, Mepln- $\beta$ , and Retnlb [101]. Key biochemical molecules with  
213 antibacterial properties in the mucus layer are bile acids and adenylate [102,103]. Bile acids impact the gut  
214 microbiota composition and interact with it [104]. Exposure to MPs decreases the concentration of serum bile acid  
215 [101].

216 c. *Microbiological barrier:*

217 Symbiotic microorganisms utilize two mechanisms to create a microbiological barrier in the gut [93]. They  
218 compete for nutrients, release antibacterial substances, and occupy attachment sites to enhance resistance against  
219 infections, ultimately improving gut health [94]. Additionally, these microorganisms can aid in nutrient digestion  
220 and absorption, providing energy to the epithelial cells [95]. The colonic cells rely on short-chain fatty acids, gut  
221 metabolites, for their growth, development, and metabolism [96]. Recent studies have demonstrated that MPs can  
222 impact gut microbial diversity and composition (**Table 2**). For example, in *F. candida*, PE-MPs completely change  
223 the diversity of the gut microbiota [14]. PS-MPs in juvenile guppies, promote the growth of *Proteobacteria* while  
224 inhibiting *Actinobacteria* [97]. Exposure to large PS-NPs increases the populations of *Firmicutes* and  
225 *Bacteroidetes* while decreasing *Proteobacteria* [98]. In zebrafish larvae, PS-MPs significantly decrease  
226 *Bacteroidetes* [99]. PE-MPs can also alter the load of *Firmicutes*, *Bacteroides*, *Proteobacteria*, and  
227 *Verrucobacterium*. *Aeromonas*, *Shewanella*, *Microbacterium*, *Nevskia*, and *Methyloversatilis* increase with MP  
228 exposure, while, *Pseudomonas*, *Ralstonia*, and *Stenotrophomonas* decrease [100]. Another study found that PS-MP  
229 exposure in zebrafish alters microbial diversity by increasing *Fusobacteria* and *Planctomycetes* and decreasing

230 *Proteobacteria*[105]. In mice, PS-MPs reduce *Bacteroides* and *Firmicutes* while elevating *Melaina* bacteria.  
 231 Additionally, MP exposure increases *Staphylococcus sp.* and decreases *Parabacteroides sp*[106].



232

233

234 **Fig.3. Schematic Representation of MP-Induced Dysbiosis. Gut Brain Axis which controls the entire**  
 235 **homeostasis of the body, upon alteration, disrupts the normal functions, resulting in Chronic Disorders.**

236

237 *d. Immune Barrier:*

238 Under the intestinal epithelium, various immune cells, such as T cells, B cells, dendritic cells, and macrophages,  
 239 can trigger immune responses by presenting antigens, generating antibodies, and secreting chemokines and  
 240 cytokines [107]. These secreted substances create the immune barrier of the intestine. For instance, secretory IgA

241 primarily exists on the surface of the intestinal mucosa to provide an immunological barrier. In adult zebrafish,  
242 exposure to PS-MP significantly impacts phagocyte and lymphocyte levels[108]. The total number of M1  
243 macrophages decreases, while the T cell population increases. Conversely, PS-MPs can decrease the number of  
244 regulatory T cells in the spleen, leading to a significant reduction in the Th17 cell population in CD<sup>4+</sup> cells [106].

245 • **Altered Homeostasis due to abnormal Endocrine Pathways:**

246 The toxic substances present on the MP surface initiate endocrine and developmental abnormalities as they act  
247 as endocrine disruptor chemicals (EDCs). They can alter hormonal expression (**Table 3**) by interfering with  
248 receptors and altering hormone synthesis, secretion, transport, and mode of action [109]. The adrenal cortex secretes  
249 glucocorticoids, which play a critical role in maintaining homeostasis, making it the most sensitive organ to EDC  
250 exposure [110]. By disrupting the HPA axis, EDCs induce various stress responses such as changes in behavior,  
251 anxiety, metabolic disorders, neurological disorders, altered immune functions, post-traumatic stress disorder  
252 (PTSD), etc. [111,112]. The presence of DEHP drastically reduces aldosterone levels, which suppress angiotensin II  
253 expression in the adult adrenal gland[110].


254 PBDEs, BPA, phthalates, and organotin are present on the MP surface and act as thyroid-disrupting chemicals  
255 (TDCs) [113]. The thyroid gland becomes hyperactive upon phthalate exposure, leading to developmental  
256 abnormalities. During childhood exposure, the weight of the thyroid gland is reduced [114,115]. Mice exposed to  
257 BPA show induced inflammatory actions in the hypothalamus by activating either astrocytes or toll-like receptors  
258 (TLR4) [116]. Both cadmium and arsenic-containing MPs reduce LH secretion and induce xeno-estrogenic effects  
259 on the inner part of the pituitary gland [117]. Arsenic-containing MPs increase mRNA expressions of genes  
260 responsible for oxidative responses, which facilitate neurological disorders, oxidative stress, and apoptosis [115].  
261 Similarly, MPs in combination with Pb and cadmium influence LH and FSH levels in proestrus rats, while Pb  
262 exposure alone causes a reduction in pituitary membrane fluidity [118].

263 When analyzing the effect of MP on male reproductive organs, MPs containing phthalate esters (PAEs) can  
264 accumulate in the testes, altering testicular weight, physiology, sperm count, and sperm vitality[119]. Additionally,  
265 MPs can lead to morphological changes in sperm, such as the loss of the sperm acrosome and the development of  
266 small-headed (cephalic), headless (acephalic), and tailless sperm, among other abnormalities[120,121]. Oxidative  
267 stress plays a significant role in male infertility, speeding up cell division and mitochondrial oxygen consumption in  
268 testicular tissues[115]. Changes in acid phosphatase (ACP), superoxide dismutase (SOD), and malondialdehyde  
269 (MDA) levels in the testes can disrupt spermatogenesis [119]. In the ovaries, granulosa cells, essential for normal  
270 ovarian development, maturation, and folliculogenesis [122] are affected by the accumulation of MPs. This  
271 accumulation can decrease the level of Anti-Mullerian hormone (AMH) in rat ovaries and granulosa cells, leading to  
272 abnormal folliculogenesis, suppression of follicle growth, reduced estradiol synthesis, and an irregular estrous cycle  
273 [115,123].

274 • **ROS-induced stress generation and DNA damage:**

275 MPs can induce ROS due to their size variation, dose variation, surface properties, and exposure times  
276 [124,125]. MP-induced extracellular ROS generation is associated with polymer aging and depends on  
277 environmental conditions [126,127]. Photooxidation or UV radiation can initiate the formation of free radicals on  
278 aged MP surfaces by either subtracting a hydrogen atom or adding it to an unsaturated carbon chain. These radicals  
279 then react with atmospheric oxygen to produce alkyl radicals with peroxy radicals as an intermediary component  
280 [124,128]. In mammalian cells, MPs are engulfed by phagocytic cells through endocytosis or pinocytosis, triggering  
281 the immunological defense mechanism [129]. To clear the ingested MP, NADPH-oxidase and/or other enzymes  
282 produce superoxide and hydrogen peroxide, leading to elevated ROS levels [126]. In signal transduction, both O<sub>2</sub>  
283 and H<sub>2</sub>O<sub>2</sub> serve as key mediators to induce oxidative stress cascades. Superoxide dismutase (SOD), catalase (CAT),  
284 and glutathione peroxidases (GPx) play important roles in the complex ROS scavenging system used by innate

285 immune cells like neutrophils. This system converts superoxide anion radical ( $O_2^-$ ) and hydrogen peroxide ( $H_2O_2$ )  
 286 into their final metabolites, water ( $H_2O$ ) and oxygen ( $O_2$ ), to maintain homeostasis [128]. According to the literature,  
 287 ROS induces Mitogen-Activated Protein Kinase (MAPK) signaling cascade activation, which can trigger autophagy,  
 288 inhibit ERK signaling, and activate p38MAPK components. This activation can be down-regulated by the  
 289 immediate enhancement of nuclear factor erythroid 2-related factor 2 (Nrf2) activities [130]. Several cascades  
 290 induced by MPs were summarized in (Fig.4).



291

292 **Fig.4. Schematic representation of MP-induced biochemical pathways which disrupt the homeostasis and**  
 293 **reestablishment of it with probiotics. A: Blocking of  $NF\kappa\beta$  pathway by Probiotics; B: SCFA mediated anti-**  
 294 **inflammation; C: Blocking of Nox-dependent pathway by Probiotics; D: Controlling ROS by CAT, SOD,**  
 295 **GPx and reduced DNA Damage**

296 In the marine copepod *P. nana* and the Mitten Crab *E. sinensis*, the MAPK downstream pathways were initiated  
297 by exposure to MPs [128]. There was a positive correlation between MP-induced ROS, elevated ERK and p38  
298 kinase phosphorylation in *P. nana* [124]. Additionally, higher expression of the Nrf-2 transcription factor upon MP  
299 exposure suggested that MPs trigger respiratory bursts via ERK and p38 MAPK pathways in an Nrf-2-dependent  
300 mechanism [124]. Excessive ROS can severely damage the cell membrane by inducing the peroxidation of  
301 membrane lipids (LPO) and other lipid structures present in the cell [128]. The LPO rate was enhanced in the brain  
302 and muscle tissues of *Dicentra*  
303 *rchuslabrax* after exposure to MPs [131]. However, in the hemocytes of the marine mussel *Mytilus* sp., MP exposure  
304 elevated ROS, but no significant change was recorded for LPO [132]. After MP exposure, LPO and 8-Oxo-Guanine  
305 damage was also observed in DNA. A 20 µm PS MP can induce DNA strand breaks in the hemocytes of *S. plana*,  
306 which is very similar to PEMP exposure [133]. Though the definite mechanism of DNA damage induced by MP is  
307 partially known, several studies suggest that MP triggers oxidative stress followed by damaging DNA [124].


#### 308 • Neurotoxicity:

309 Exposure to MP can also induce neurotoxicity, which is associated with neurodegenerative diseases. MP-  
310 mediated ROS induction, activation of microglia in the brain, inhibition of acetylcholinesterase (AChE), and  
311 elevation of circulating pro-inflammatory cytokines can trigger *in vivo* neurotoxicity in aquatic animal and  
312 mammalian models [134]. AChE breaks down acetylcholine (ACh) into choline and acetic acid, with ACh acting as  
313 a neurotransmitter to control the function of motor neurons [128]. AChE inhibition leads to the accumulation of  
314 ACh in the synaptic cleft, causing issues with muscular movement [128]. Exposure to MP induces AChE inhibition  
315 in the brain of *Phrynomantis microps* [135]. However, in *S. plana*, exposure to both PE and PS microspheres induces  
316 anti-cholinesterase activities [128]. MP (5-20 µm) causes inflammation after inducing a neurotoxic impact in animal  
317 models [136]. Experimental results using *C. elegans* demonstrated that because nematodes lack the blood-brain  
318 barrier (BBB), their neurotoxicity is significantly more severe [137]. The present study in SH-SY5Y cells showed  
319 that hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and AChE metabolism are directly related, to ROS-dependent abnormalities in the  
320 cholinergic system in brain cells. The levels of AChE decrease as H<sub>2</sub>O<sub>2</sub> alters the enzyme and its isoform's  
321 structure allosterically [138]. Moreover, it has already been established that in MP-induced neurotoxicity, MP serves  
322 as a significant carrier of heavy metals. The biofilm on its surface accelerates the accumulation of metal ions [30].  
323 However, whether metal is present or absent within the cell determines metal dysbiosis. In many neurodegenerative  
324 diseases, an imbalance of metal homeostasis initiates a cascade that ultimately leads to neural network dysfunction.  
325 Neural dysfunction results in oxidative stress, aggregation of misfolded proteins, mitochondrial damage,  
326 malfunction, autophagy, and energy depletion [139].

#### 327 • Inflammation

328 When various toxicants, pathogens, MPs/NPs, and xenobiotics are exposed, the body responds by triggering  
329 inflammation, which is a localized defense mechanism. It can be a very destructive process with multiple levels of  
330 complexity [140,141]. MPs can trigger the inflammatory response at the molecular level by activating pro-  
331 inflammatory cytokines, signaling molecules secreted mainly by immune cells (leukocytes) [142]. Though the exact  
332 mechanism is not very clear, pro-inflammatory responses can be related to oxidative stress and lysosome membrane  
333 disintegration [128]. MP-induced inflammation, at its second and third levels, can initiate cellular responses and  
334 tissue damage. Inflammatory tissue damage was detected in various *in vivo* models of MP exposure [136]. Immune  
335 effector cells such as phagocytic cells encounter them frequently as they provide the first line of defense against  
336 foreign particles. *In vitro*, cell line models have already shown that MPs can not only regulate cytokine release but  
337 also alter the expression of inflammatory gene responses. Gene expression of pro-inflammatory cytokines IL6, IL8,  
338 and IL1β is up-regulated after PS-MP exposure in human gastric adenocarcinoma cells, which induces cell death  
339 [143]. In the THP-1 monocytic cell line, a size-dependent cytokine release study revealed that IL6 production  
340 increases with an enhancement of particle size; however, for IL8 secretion, the opposite trend was obtained [128]. In

341 addition, exposure to 0.5  $\mu\text{m}$  PS-MPs enhanced both the mRNA levels and protein expression of IL1 $\alpha$ , IL1 $\beta$ , and  
 342 IFN in the zebrafish gut [140]. Following a seven-day exposure period, zebrafish gills, liver, and gut began to  
 343 accumulate PS MPs (5  $\mu\text{m}$ ), which triggered the normal inflammatory damage processes of vacuolation,  
 344 leukocyte/neutrophil infiltration, necrosis, and lipidosis in the liver[128]. Liver histopathology findings support the  
 345 finding, with elevated levels of SOD and CAT activities inducing oxidative stress followed by an inflammatory  
 346 response [136].



347  
 348 **Fig.5. Disruption of Homeostasis. A. Normal condition in which Gut-Brain Axis regulates physiological,**  
 349 **biochemical and neuronal pathways, B. MP-induced PD brain in which altered Gut-Brain Axis triggers**  
 350 **several altered mechanisms to hinder physiological, biochemical and neuronal pathways**

351 • **Dysfunction of Bowel:**

352 Exposure to MP can cause gut dysbiosis, leading to discomfort in the bowel. When exposed to MP, low vagal  
353 activity reduces bowel contractions, motility, and can cause constipation. Conversely, high vagal activity can  
354 enhance bowel contractions, potentially leading to diarrhea[144]. Similar to Irritable Bowel Syndrome (IBS), the  
355 sympathovagal balance is disrupted in MP-exposed gut [145]. Previous studies have shown that female IBS patients  
356 with increased parasympathetic may experience constipation due to lower vagal activity, which is directly linked to  
357 severe abdominal pain [146]. The stress axis and the autonomic nervous system are closely linked with elevated  
358 levels of corticotrophin-releasing factor (CRF) expression increasing sympathetic tone during constipation [147].  
359 The parasympathetic nervous system stimulates smooth muscle contractions and secretory actions in the GI tract,  
360 while the sympathetic nervous system inhibits these processes. The parasympathetic afferent pathway sends  
361 information about gastric accommodation and gastric-colic reflex to corticolimbic structures [148]. This information  
362 is also transmitted to areas of the brain such as the hippocampus, amygdala, prefrontal cortex, and hypothalamus for  
363 processing [149]. Through sympathetic afferent pathways, signals reach the thalamus and then the sensory cortex  
364 and pain matrix via the spinal cord [150].

#### 365 • Disruption of Cell Organelle:

366 Mitochondria are organelles responsible for generating intracellular ROS by using one-electron carriers such as  
367 cytochromes, iron-sulfur proteins, and various oxidases. Instability in the mitochondrial membrane potential is the  
368 main reason for excessive ROS generation[128]. In mice and rotifer *B. koreanus*, exposure to PS-MPs has been  
369 recorded to cause mitochondrial membrane dysfunction, which requires further validation [124]. It is already known  
370 that excessive oxidative stress in the cytosol can stimulate Na/K trans-membrane channel opening in mitochondria.  
371 This elevated membrane channel ionic flux disrupts the mitochondrial membrane potential and releases free radicals  
372 through the ROS-induced ROS-release"(RIRR) mechanism [128]. In human pulmonary cells, MPs induce apoptosis  
373 by increasing intracellular ROS levels and altering the mitochondrial membrane potential, directly affecting cell  
374 viability [151]. Alteration of the membrane potential and impairment of cellular energy metabolism are mediated by  
375 a NADPH oxidase 4 (NOX4)-dependent mechanism that causes mitochondrial dysfunction in the respiratory  
376 epithelium (**Fig.4**). Furthermore, a recent study revealed that the release of mt-DNA into the cytoplasm indicates  
377 MP-induced mitochondrial damage and dysfunction followed by mitochondrial breakdown [152]. In Caco-2 cells,  
378 MPs induce alterations in mitochondrial depolarization and inhibit ATP-binding cassette transporter activity leading  
379 to changes in ATP synthesis and increased toxicity[140]. Additionally, MP-induced mitochondrial ROS accelerates  
380 the expression of various proteins targeting BCL2-associated cell death, endoplasmic reticulum stress, inflammation,  
381 and autophagy, ultimately leading to kidney damage and protein leakage[13]. Moreover, MPs can induce lipid  
382 accumulation in macrophages under acute oxidative stress conditions, initiating macrophage foam cell formation, a  
383 characteristic feature of atherosclerosis pathology[153,154]. MP-induced mitochondrial membrane damage depends  
384 on particle size [124].

385 Another cellular organelle, the lysosome, contains a variety of hydrolytic enzymes that can digest foreign  
386 substances or phagocytose the target cell. Lysosomes are severely affected by MP/NP exposure as membrane  
387 stability is altered. Upon exposure to MPs, lysosomal hydrolase activity was reduced, which can alter the lysosomal  
388 pH value and impair autophagy [155]. Presently, lysosomal membrane stability is being used as a biomarker to  
389 evaluate the effect of MPs [156]. In blue mussels (*Mytilus galloprovincialis*), the function of the lysosome was  
390 completely disrupted after exposure to MPs [128]. Furthermore, experimental evidence also indicates a correlation  
391 between MP-induced ROS generation, oxidative stress, and disruption of lysosomal function as MPs are detected in  
392 the lysosome [157]. Though the exact mechanisms of lysosome disruption by MPs are not fully understood, MPs  
393 can induce lysosomal dysfunction either directly or indirectly. In direct damage, MPs can enter the cell via  
394 endocytosis or permeation and initiate lysosomal disruption during their digestion [128]. Experimental evidence  
395 revealed that PS MPs altered the lysosome's ability to maintain an acidic pH and inhibit autophagy. As a result, lipid  
396 droplets (LDs) accumulated in PS MP-infected macrophage lysosomes, triggering cellular foam formation [158]. In  
397 the indirect mechanism, MPs trigger the production of excessive ROS and disrupt the lysosome, as the lysosomal

398 membranes are highly susceptible to ROS [159]. Cathepsins are released into the cytoplasm by enlarged lysosomes,  
399 and these enzymes ultimately cause damage to the mitochondria and subsequent apoptosis [160]. The toxicity of  
400 ROS scavengers, such as N-acetylcysteine, lessen macrophages when they interact with the MP surface, indicating  
401 the harmful effects of ROS on lysosomes and macrophages[161].Additionally, experimental evidence indicated that  
402 the plastic surface of disposable laboratory equipment, such as centrifuge tubes, enhances amyloid fibrillation by  
403 interacting with prions and amyloids. Windheim et al., (2022) conducted an experiment using centrifuge tubes made  
404 of polycarbonate, polystyrene, acrylonitrile copolymer, and polypropylene. They found that tubes made of  
405 polystyrene showed higher levels of amyloid absorption (**Fig.5A-B**)[162].

## 406 PROBIOTIC A NEW APPROACH TO CONTROL MP-INDUCED GUT DYSBIOSIS


407 Microbiota, which plays a crucial role in maintaining the body's immunity, can be utilized in the treatment  
408 of metabolic disorders and mental illnesses. Exposure to MP significantly changes the composition of the gut,  
409 leading to the development of complications and chronic disorders. Probiotics, a group of beneficial  
410 microorganisms, play a critical role in regulating microbiota [163]. In PD, probiotics help improve GI function by  
411 reducing gut permeability, bacterial translocation, and neuro-inflammation in the ENS [164]. Probiotics show great  
412 promise in treating various disorders, including neurodegenerative diseases, by connecting hormonal and  
413 biochemical pathways to enhance gut and brain health (**Fig.6**) [165]. Consuming probiotics either alone or in food  
414 enhances antioxidant activity or reduces oxidative damage in cells. *Lactobacillus reuteri* can speed up gastric  
415 emptying and decrease regurgitation in infants. It is well-established that neuroinflammation is closely linked to  
416 neurodegeneration, behavioral deficits, and other neurological tissues[166,167]. Toll-like receptors (TLR) and  
417 NOD-like receptors (NLR) cells identify microbe-associated molecular patterns (MAMPs) from bacteria triggering  
418 signaling cascades that result in the expression of pro- or anti-inflammatory cytokines (**Fig.4**). Probiotics have the  
419 potential to be used in the treatment of neuroinflammation and neuronal diseases. Reports suggest that probiotic  
420 beverages may help alleviate both the motor and non-motor symptoms of PD. Furthermore, consuming *L. salivarius*  
421 LS01 and *L. acidophilus* significantly reduces proinflammatory cytokines while increasing anti-inflammatory  
422 cytokines. By reducing levels of pro-inflammatory cytokines, probiotics can enhance intestinal barrier integrity in  
423 patients with inflammatory bowel disease. This is achieved by decreasing the differentiation of CD4<sup>+</sup> T cell into Th<sub>2</sub>  
424 cells and inhibiting nuclear factor kappa B both of which are crucial in controlling inflammation [145].

425 Probiotic strains such as *Lactobacilli* and *Bifidobacteria* can synthesize antioxidants, vitamins, and  
426 bioactive compounds, reduce free radicals, and have beneficial effects on disorders associated with oxidative stress,  
427 including PD [164]. In PD patients, LA02 downregulates ROS in the early stages of the disease. Consumption of  
428 yogurt and probiotics such as *Bifidobacterium* sp. and *Lactobacillus* sp. can improve bowel contractions, motility,  
429 and intestinal balance [168]. They can enhance barrier function by promoting mucus secretion from goblet cells. The  
430 probiotic *L. plantarum* BMC12 can secrete extracellular proteins, that weaken pathogen attachment and protect  
431 the intestinal barrier [169]. Probiotic formulations also enhance CNS activity by modulating inflammation and  
432 interacting positively with the gut microorganisms. Due to increased intestinal permeability to endotoxins, PD  
433 patients have high levels of pro-inflammatory cytokines (lipopolysaccharides) in their gut. The presence of amyloids  
434 can also harm gut health by increasing pro-inflammatory cytokines [170]. Probiotics safeguard the brain by  
435 preventing stress-induced synaptic dysfunction between neurons. In rats, two weeks of probiotic treatment  
436 significantly reduces the levels of ACTH and corticosterone, indicating its suppressive effects on the HPA axis.  
437 Probiotics have the potential to prevent or reverse physiologic damage caused by HPA-mediated chronic stress  
438 [171]. In rats injected with A $\beta$  in the lateral ventricle, treatment with *Lactobacillus acidophilus*, *Bifidobacterium*  
439 *longum*, and *Bifidobacterium bifidum* in combination improves impaired spatial cognition and restores synaptic  
440 plasticity [172].

441 The manufacture of non-specific antimicrobials for numerous illnesses, transmissible antibiotic resistance  
442 genes, variable host-specific probiotic capacity, and toxic metabolites are some of the drawbacks of conventional  
443 probiotics. Over time, unique behaviors have been observed in conventional probiotic bacteria due to genetic



444 alteration, opening up new possibilities. It is now possible to create therapeutic systems that surpass the capabilities  
 445 of wild-type microorganisms through the integration of novel gene editing methods with distinctive design  
 446 strategies. Bioengineered probiotic LAB is one of the next generation of whole-cell-mediated biotherapies being  
 447 developed to treat human ailments [173]. Probiotics are now more often seen as microbial "physicians," rather than  
 448 just as a means of delivering medication. Engineered bio-therapeutics have several advantages over microbiota-  
 449 directed techniques such as FMT [174]. The primary advantage of genetic engineering is its capacity to provide  
 450 functions that endogenous microbiota cannot naturally exhibit [175]. Engineered probiotics have the potential to  
 451 supply the host's mucosal immune system with enzymes, vaccines, antibiotics, and cytokines [173]. This could  
 452 provide a more efficient drug delivery technique than abiotic treatments. Additionally, probiotics can be altered to  
 453 incorporate biotic sensors, which serve as non-invasive diagnostic instruments [176]. Probiotics have mostly been  
 454 utilized to deliver proteinaceous medications that are easily synthesized or modified by commensal bacteria [177].  
 455 Therefore, the biosynthetic capacities of common probiotics need to be continuously extended to boost the  
 456 flexibility of probiotic-based treatments [178]. Furthermore, artificial probiotics with the ability to respond to stimuli  
 457 and alter their activity in response to conditions that are specifically customized to them are required [173].



**459 Fig.6. Probiotics the New Therapeutic Approach to Control Gut Dysbiosis Induced by MPs**

460 The main challenge in developing probiotics is determining the optimal platform[178]. Safety and host  
461 survival are difficult trade-offs [177]. Since some engineered *Lactobacillus* species are not native to the human  
462 microbiota, they are quickly flushed out by better-adapted microorganisms, which reduces their therapeutic effects  
463 [179]. Probiotic engineering tools should be extended to encompass resident microbiota to further the engineering of  
464 host-microbiota interactions. Another significant issue in the production of probiotics is the generation of effective  
465 integration and expression of foreign DNA. Essential functions may be hampered by off-site alterations brought on  
466 by exogenous DNA inclusion. Off-site modifications may also result in the production of a hazardous metabolite  
467 [176]. Thus, extra caution should be used when altering the genome of genetically modified probiotics to avoid  
468 compromising the organism's inherent advantageous traits or resulting in the production of dangerous substances in  
469 organisms that have traditionally been Generally Regarded as Safe (GRAS).

**470 COMMERCIAL ASPECT OF PROBIOTICS**

471 Personalized medicine is an innovative approach that identifies the unique metabolism associated with each  
472 patient's complex condition, considering individual variations in genetics, environment, and behavior[180]. This  
473 new approach can predict how an individual will respond to different foods and medications by regular assessing  
474 their microbial load, offering the opportunity to create new disease-specific treatment options. With these factors, in  
475 mind, the development of designer probiotics and next-generation probiotics could be a safe and effective strategy in  
476 the era of personalized medicine, helping to improve targeted diseases through modifications of the gut flora. Over  
477 the past few decades, the gut microbiota has emerged as a valuable indicator for prognosis, health, and drug efficacy  
478 [181]. Research in microbiology has shown that both GI and non-GI diseases are linked to imbalances in the gut  
479 microbiota. Since each disease presents uniquely and patients may respond differently to the same treatment due to  
480 variations in disease location, treatment methods, and diagnostic tools, it is crucial to embrace the concept of  
481 personalized therapy tailored to each patient's characteristics. Next-generation probiotics have become a promising  
482 customized treatment method due to their capability to alter the gut microbiota and potentially improve the targeted  
483 condition. There are two common approaches to creating next-generation probiotics. The first involves identifying a  
484 strain associated with a specific health phenotype and confirming its ability to replicate that phenotype using  
485 appropriate experiments. The second approach entails identifying a potent substance capable of reversing the disease  
486 pattern and incorporating it into a well-researched probiotic strain that can act as a delivery system. Various  
487 bacterial strains have been discovered and studied as natural growth promoters (NGPs) for treating pathogenesis,  
488 obesity, cancer, inflammatory bowel disease (IBD), and other disorders. The recent development of CRISPR/Cas9  
489 genome editing tool has enhanced the platform for more precise genome editing, allowing for the addition of new  
490 features or the activation or deactivation of genes to promote host colonization and enhance human health.

491 The following characteristics of potential probiotic strains could mitigate or even reverse the effects of  
492 heavy metal toxicity: 1) Strong antioxidant properties; 2) immunoregulatory properties to help them adapt to  
493 changes in the intestinal environment induced by heavy metals; 3) good intestinal adhesion or colonization ability to  
494 play beneficial roles in the gut; and 4) high tolerance to acid and bile, allowing them to remain active in the GI tract.  
495 These characteristics enable them to bind, tolerate, or detoxify heavy metals with remarkable effectiveness. *L.*  
496 *plantarum* TW1-1 was used to neutralize Cr toxicity; *L. plantarum* CCFM8610 and *Bacillus cereus* were used to  
497 neutralize Cd toxicity; *L. plantarum* CCFM8661 and *L. reuteri* P16 were used to neutralize Pb toxicity; and *L. brevis*  
498 23017 was used to counteract Hg toxicity[182–184]. By promoting intestinal peristalsis and sequestering heavy  
499 metals in the intestines, these strains can reduce the absorption of heavy metals in the gut and reverse changes in the  
500 gut microbiota caused by heavy metals. This, in turn, aids in the removal of heavy metals from the stool  
501 [185]. Enzymes secreted by microorganisms have previously been shown to be capable of breaking MP polymer  
502 chains [186]. ATP-binding cassette transporters, which facilitate the hydrolysis process, mediate the uptake and  
503 outflow of tiny fragments across the cell membrane in both prokaryotic and eukaryotic cells. Enzymatic processes  
504 such as hydroxylation, hydrolysis, and oxidation convert the MPs into monomers [187]. High molecular weight MPs

505 are broken down by extracellular enzymes before being incorporated into microbial cells [188]. The degraded MPs  
506 are then catabolically directed within the microorganisms to produce energy for intracellular polymerization and  
507 integration into cellular structures [189]. Using function- and sequence-based metagenomic approaches powered by  
508 metagenomic (MG) methodologies, a search is conducted for bacteria that degrade MPs. The function-based  
509 strategy involves screening for different enzymes at random, while the sequence-based technique predicts multiple  
510 efficient genes in producing MP-degrading enzymes [188]. Selecting a probiotic strain that counteracts severe metal  
511 toxicities and using genome editing to modify genes that encode plastic breakdown could potentially resolve the  
512 issue. However, further experimental investigation using various biological models is necessary to support this  
513 theory.

514 Among them, trials are ongoing with *L. rhamnosus* and *Lactobacillus helveticus* against acute  
515 gastroenteritis. Although these probiotic strains were found to be stable, the duration and severity of diarrhea and  
516 vomiting remained unchanged between the control and treatment groups. On the contrary *Bacillus clausii*  
517 significantly reduced the duration of diarrhea and hospital stay compared to controls. Additionally, 400 infants were  
518 randomly assigned to a control formula or a test formula containing prebiotic bovine milk oligosaccharides and the  
519 probiotic *Bifidobacterium lactis* to assess acute gastroenteritis. The promising results of the probiotic strains make  
520 the trial very crucial [190]. Similarly, a significant reduction in diarrheal and respiratory infections over a 6-month  
521 follow-up period was recorded with *L. reuteri* DSM 17938 [191]. This strain was found to be effective against infant  
522 colic. In addition, *L. plantarum*, *L. casei*, *Lactobacillus gasseri*, *B. longum*, *B. bifidum* as well as *Lactobacillus*  
523 *delbrueckii* and *Streptococcus thermophilus* were also tested against IBS, *Helicobacter pylori* infection, *Clostridium*  
524 *difficile* infection, traveler's diarrhea etc., [190]. In a clinical trial it was observed that *L. rhamnosus* GG (LGG) was  
525 effective against infant asthma by reducing the concentration of exhaled nitric oxide. This strain was also equally  
526 effective in reducing the occurrence of allergic symptoms and accelerating the acquisition of cow's milk protein  
527 tolerance [190]. However, *Lactobacillus reuteri*, *Lactobacillus rhamnosus* HN001, *Lactobacillus*  
528 *paracasei* subsp. *paracasei* F19, *Bifidobacterium bifidum*, *B. lactis*, and *Lactococcus lactis* did not show any  
529 significant reduction in asthma symptoms [192]. The risk of atopic dermatitis in children up to the age of two can be  
530 reduced if the pregnant mother is receiving a combination of *Lactobacillus rhamnosus*, *Bifidobacterium*  
531 *breve*, and *Propionibacterium freudenreichii*. Australian researchers conducted a study that used probiotic and  
532 peanut oral immunotherapy (PPOIT) [193]. The therapy lasted for 18 months, and *L. rhamnosus* CGMCC1.3724 was  
533 used as a probiotic with significant improvement in symptoms [194].

534 Certain strains of *Lactobacillus* including *Lactobacillus plantarum* ECGC 13110402, *Lactobacillus*  
535 *fermentum* ME-3, *Bifidobacterium lactis* HN019, *Streptococcus thermophilus*, *Lactobacillus acidophilus* L1,  
536 *Bifidobacterium longum* BL1, and *Lactobacillus plantarum* 299v have shown promise in treating  
537 hypercholesterolemia in clinical trials [193]. Bacteriocins controlled the condition by acting as inhibitors of the  
538 angiotensin-converting enzyme (ACE) [195]. Clinical trials have shown that supplements containing *Lactobacillus*  
539 *casei* W56, *Lactococcus lactis* W19, *Lactobacillus acidophilus* W22, *Bifidobacterium lactis* W52, *Lactobacillus*  
540 *paracasei* W20, *Lactobacillus plantarum* B62, *Lactobacillus plantarum* W23, and *Lactobacillus salivarius* W24  
541 decreased intestinal inflammation in AD patients. Mixtures of *Lactobacillus acidophilus* ( $2 \times 10^9$  CFU/g),  
542 *Lactobacillus reuteri* ( $2 \times 10^9$  CFU/g), *Bifidobacterium bifidum* ( $2 \times 10^9$  CFU/g), and *Lactobacillus fermentum*  
543 ( $2 \times 10^9$  CFU/g) were administered to Parkinson's patients for 12 weeks. In addition to controlling the gut-brain axis,  
544 probiotics can efficiently degrade and/or adsorb environmental chemicals such as endocrine disruptors (EDs).  
545 Lyophilized cells of LAB could remove BPA through an adsorption mechanism [196]. Similar findings have been  
546 observed in the yeast *Pichia pastoris* [197,198]. Researchers have studied the environmental BPA detoxification and  
547 degradation capacities of *Lactobacillus* spp., *Bifidobacterium* spp., and *Streptococcus thermophilus* [199].  
548 Furthermore, the concentration of SCFA significantly increased in the microbiota of probiotic-treated mice [200].  
549 Dairy *Lactobacilli* can bind to and break down pesticides [201] and BPA [202], suggesting the potential for a  
550 financially viable bioremediation technique using microbial cells to address the effects of increased ED exposure  
551 [203]. Probiotics can also block pathogen attachment by producing mucin from goblet cells [204].

552 Probiotics appear to be safe based on the majority of research, with no true contraindications. However, in  
553 light of a few incidents, certain individuals should proceed with caution. Patients with small gut syndrome,  
554 compromised immune systems, or advanced age should consider any potential adverse effects before starting  
555 [205]. Given that probiotics are widely consumed, probiotic-associated illnesses are uncommon [206]. Although  
556 reporting has not been consistent or comprehensive, reported adverse events in probiotic clinical trials are usually  
557 not product-related [207]. Almost all reports of infections by common probiotic genera or species are restricted to  
558 patients with impaired immune systems. Nevertheless, it has seldom been established that the bacteria extracted  
559 from the illness are the same strain as the probiotic organism that was given [208]. To investigate potential negative  
560 effects, Hempel et al. analyzed 622 human probiotic intervention studies. Out of these, 387 studies documented the  
561 presence or absence of specific adverse outcomes, such as fungemia and bacteremia, which could have been caused  
562 by probiotic exposure [209,210]. Overall, the relative risk (RR) for gastrointestinal infections or other adverse  
563 events in probiotics-exposed patients was not significantly higher than that of controls in randomized controlled  
564 trials [209]. Despite the abundance of research, the current literature does not provide definitive answers on the  
565 safety of probiotic interventions, the scientists note in their conclusion. For example, the efficacy of probiotics in  
566 Irritable Bowel Diseases (IBDs) has been assessed in numerous studies and meta-analyses. However, while some  
567 authors have reported data on probiotic-related adverse effects [211], there is a lack of information regarding meta-  
568 analyses.

569 Similar to Ford *et al.* (2018) systematic review and meta-analysis of 36 trials involving 4,183 patients on  
570 the effectiveness of probiotics, prebiotics, synbiotics, and antibiotics in treating irritable bowel syndrome (IBS), it  
571 was found that probiotic-treated patients experienced adverse events more frequently than those treated with a  
572 placebo, although the RR was not significantly higher. The authors also observed significant variation between  
573 research studies [212]. The duration of probiotic therapy is likely to impact the results. Formulations with a low  
574 bacterial concentration may have no effect or may work counter to expectations while only formulations with a high  
575 bacterial load may have a favorable effect. For instance, children who received daily doses of *Lactobacilli* equal to  
576 or greater than  $10^{10}$  CFU experienced a significant reduction in the duration of their diarrhea. Additionally, some  
577 individuals taking probiotics may experience a temporary increase in edema and gas production, as well as  
578 constipation, which typically resolves within a few weeks [201,202]. Several lactic bacteria produce bioactive  
579 compounds such as histamine, tyramine, and phenylethylamine, which can lead to headaches and other  
580 symptoms [215]. Bennet (2016) noted that gastrointestinal symptoms were the most common side effect in a review  
581 discussing the quantitative risk-benefit analysis of probiotic use in IBS and IBD [216]. However, it can be  
582 challenging to differentiate between gastrointestinal symptoms caused by the natural progression of IBD and those  
583 induced by probiotic exposure [198,205]. Liu *et al.* (2016) demonstrated the negative effects of probiotic  
584 administration in a tilapia model, simulating immune-compromised conditions in humans [218]. Abrupt suspension  
585 of probiotics led to gut dysbiosis in the fish model making them susceptible to *Aeromonas hydrophila* infection.  
586 They clearly stated that the risks identified in their study were relevant for immune-compromised patients or  
587 neonates, as gut dysbiosis and opportunistic pathogen infection could lead to serious problems. Claudiano *et al.*  
588 (2020) presented experimental evidence of *Aeromonas hydrophila* infection causing hemolysis, neurological  
589 disturbances, and high mortality in *Piaractus mesopotamicus* [219]. Yue *et al.* (2022) also reported on heavy metal-  
590 induced gut dysbiosis followed by *Aeromonas* infection which initiated brain injury in common carp [206]. Hemin, a  
591 degraded byproduct of hemoglobin, can activate microglia and play a critical role in Intracerebral Hemorrhage  
592 (ICH)-associated inflammatory brain damage [220]. Dodd *et al.* (2022) demonstrated a correlation between brain  
593 injury and neurodegeneration [221].

## 594 CHALLENGES AND FUTURE ASPECTS

595 Human exposure to MPs has been estimated to range from tens of thousands to millions per year, equating  
596 to several milligrams per day. The presence of biofilm on MP surfaces exacerbates the harmful effects of these  
597 smaller units. Bacterial adherence is facilitated by the high degree of pores and functional groups present in small-

598 sized, degraded MPs, which have a more defined surface area. Contaminant circulation and adsorption-desorption  
599 on MPs are crucial factors that influence the lethality, bioaccessibility, relocation, and residual concentration of  
600 pollutants [222]. This biofilm can capture nearby metals, forming metal aggregates, that make them unavailable for  
601 essential cellular homeostasis, ultimately leading to metal-induced neurotoxicity [30]. The essential metals are  
602 necessary for the brain parenchyma to perform its normal biological functions. Metals such as sodium, potassium,  
603 magnesium, calcium, copper, manganese, iron, zinc, molybdenum, nickel, etc., play an important role in regulating  
604 the physiological pathways such as electron transport chain, oxygen transport, protein folding, synthesis of  
605 neurotransmitters, redox reactions, cell adhesion, metabolism, and defense. Each brain compartment has a unique  
606 metals concentration. These metals are essential in the diet to maintain homeostasis but can be toxic in excess. In  
607 neurons of invertebrates, nanoplastics appear to upregulate neurotransmitter precursors and downregulate  
608 acetylcholine and gamma-aminobutyric acid (GABA) reuptake transporters, both mechanisms of which are  
609 indications of neurotoxicity[223,224]. In vertebrates, the accumulation of micro and nanoplastics led to toxicity in  
610 the liver and intestines, inducing dysfunction, metabolic changes, inflammation, gene alteration, and increased  
611 oxidative stress [225]. They also disrupt the degranulation of neutrophils [226,227]. Studies also reported that MPs  
612 were deposited in lipid-rich brain tissue, resulting in behavioral alteration. Exposure to PS-MPs caused alterations in  
613 gut microbiota composition and showed higher toxicity in mice with dietary restriction, which leads to gut barrier  
614 dysfunction due to elevation in pathogenic bacteria, increased intestinal permeability, and decreased mucus secretion  
615 and water intake [228]. A decrease in microbial diversity and an increase in proinflammatory species characterize  
616 dysbiosis. This imbalance in microbiota triggers inflammation and produces genotoxins such as carcinogenic  
617 metabolites [229]. Not only that chronic fatigue, digestive problems, trouble urination, acid reflux or heartburn are  
618 the complications found in association with gut dysbiosis.

619 Several studies proved that in PD, gut microbiota alteration, reduced short-chain fatty acids, intestinal  
620 permeability disruption and intestinal inflammation [230], shows the interconnection between the enteric and central  
621 nervous systems. Levodopa, a precursor of dopamine, is an effective drug for PD [231]. Long-term consumption of  
622 levodopa can lead to dyskinesia, motor fluctuations, and hallucinations and it is less effective as a therapeutic for  
623 mental changes, postural instability, gait difficulty, and dysphagia [232,233]. Levodopa treatments can also lead to  
624 mild adverse effects like nausea, dizziness, headache, and drowsiness [231]. Thus, the intervention of new  
625 formulation is the basic requirement to overcome neuronal issues. Formulated probiotics like *Bifidobacterium*  
626 *animalis*, *Ruminococcaceae*, *Lachnospira*, *Lactobacillus fermentum* and *Klebsiella oxytoca* significantly improved  
627 the degradation of tryptophan, gamma-aminobutyric acid, short-chain fatty acids, dopamine levels and serum acetic  
628 acid [234]. The gastrointestinal tract serves to maximize the rate of nutrient gain to maintain the integral nutrient  
629 balance [235]. The chemical properties of plastics such as net electrical charge are altered due to environmental  
630 interaction, affecting the interactions with organic molecules [236]. The constituent and function of the intestine  
631 microbes can be altered by probiotics, prebiotics, and synbiotics [237]. Due to their capability to regulate the  
632 composition of intestinal flora, they can reduce inflammation and oxidative stress, and enhance the crucial active  
633 metabolites [238]. MPs can trigger inflammation and excessive production of ROS, which can disrupt essential  
634 cellular activities [239]. Probiotics can reduce polyethylene MPs-induced oxidative stress and also restore  
635 antioxidant enzyme activities, which include superoxide dismutase, catalase, glutathione S-transferase, and  
636 glutathione peroxidase [240]. Furthermore, probiotics are the preferred choice in modern times for establishing gut  
637 homeostasis due to their high potential and minimal side effects.

638 Earlier studies have been conducted on the formation of MPs, removal strategies, and their exposure to  
639 terrestrial, aquatic, and marine habitats. However, research on the toxicities of MPs in mammals and the human  
640 brain, leading to neurodegeneration, is limited. As a result, there is a gap in understanding the risk of MPs exposure  
641 to humans due to the lack of validated methodologies, approved reference materials, and consistency in analytical  
642 processes. The potentially harmful effects of various types of MPs on mammal and human health remain unknown  
643 due to the significant variation in particle size, shape, and chemical composition of plastics. Additionally, there is a  
644 lack of animal models that accurately reflect the effects of MPs on humans. More research should be conducted

645 using models of other animal species, such as rabbits, birds, pigs, and monkeys. Probiotics have shown promising  
646 results in treating gut dysbiosis and other GI disorders, but there are a few drawbacks to consider. Some of these  
647 obstacles include using obligate anaerobes as probiotics to overcome gut transit survival difficulties, identifying and  
648 isolating novel prebiotic sources, and producing synbiotics at an affordable cost. Low rigidity and ineffective  
649 marketing are post-production issues for probiotics because they are not recognized as medical products in many  
650 countries [59]. Personalized medicine is an innovative approach that considers individual differences in genetics,  
651 environment, and behavior to determine the unique metabolism associated with each patient's complex condition.  
652 Metabolic issues and mental disorders can be addressed using microbiota, which is crucial in maintaining the body's  
653 immunity. Probiotic supplementations also enhance CNS function by reducing inflammation and promoting a  
654 beneficial relation with the gut microorganisms. Probiotics can protect the brain by preventing the breakdown of  
655 synaptic connections between neurons caused by stress. Nowadays, probiotics are seen as microbial "physicians" as  
656 opposed to merely a means of delivering medication. In developing probiotics, we have discovered that the main  
657 challenge lies in selecting the most effective platform [178]. A challenging trade-off is finding a balance between  
658 the survival and safety of the host [177]. The therapeutic effects of certain engineered *Lactobacillus* species are  
659 reduced because they are quickly eliminated by more well-adapted microbes, as they are not native to the human  
660 microbiota.

661         Considering all the potential effects of MP exposure on humans, which can lead to gut dysbiosis followed  
662 by neurodegeneration, it is urgently necessary to conduct extensive studies with human and mammal animal models  
663 to determine the impact of probiotics supplementation in establishing homeostasis. Comprehensive scientific  
664 research results will be used to raise awareness among everyone, including the public, lawmakers, the education  
665 sector, and industry. Furthermore, to control the excessive use of plastic items, strong administrative rules and  
666 policies must be implemented. Without implementing these measures, the overall health of ecosystems and living  
667 organisms will inevitably deteriorate in the future. Therefore, more research on this specific issue is needed to  
668 protect the safety of aquatic and terrestrial life and to understand the mechanism of its cytotoxicity. We believe that  
669 both the government and industry must make significant efforts to protect people from MP exposure. These efforts  
670 should include keeping plastic out of food, conducting thorough wet cleanings every few days, carefully selecting  
671 building materials and personal care products and considering probiotics supplementation as a therapeutic approach  
672 for reestablishing homeostasis. Additionally, governments should fund studies to identify and measure the dangers  
673 of MPs. We advocate for interdisciplinary collaboration among scientists to enhance our understanding of the effects  
674 of early life MPs and chemical exposure. The Earth is currently grappling with a pervasive and insidious issue of  
675 plastic pollution and without a clear long-term solution in sight, it is crucial to thoroughly define and explore the  
676 hazards, particularly concerning human health.

## 677 CONCLUSION

678         At present, the main reason humans are exposed to MPs is the increasing consumption of plastic. MPs have  
679 the ability to absorb, release, and act as reservoirs for various toxic chemicals and heavy metals, allowing these  
680 toxins to enter the human body and cause serious health issues. As the concentration of MPs increases in the body,  
681 they begin to modulate several biochemical and physiological pathways by altering the gut-brain axis. This can lead  
682 to inflammatory lesions, tissue degradation, ROS, metal imbalance, changes in gut phenotype, gut barrier function,  
683 endocrine secretion, and neurodegeneration. While there is limited information on the stages of plastic in the human  
684 diet, it is evident that regardless of degradation, MPs contaminate the environment, enter the body through  
685 contaminated foods, and disrupt intestinal homeostasis. Recent studies have shown that nano- and microplastics  
686 have various effects on the intestines, including disrupting intestinal homeostasis, altering gut permeability, and  
687 affecting levels of cytokine secretion. Since the human diet plays a significant role in disrupting gut microbes and  
688 causing disorders, probiotics are a suitable and compassionate therapeutic target to manage gut dysbiosis and protect  
689 bi-directional axes such as the gut-brain axis, gut-liver axis, gut-lung axis, and gut-skin axis. The altered gut induced  
690 by MP consumption also leads to oxidative stress, inflammation, and reproductive issues. Probiotics can effectively

691 control ROS, inflammation, and reproductive problems. In conclusion, probiotics play a crucial role in managing  
 692 MP-induced gut dysbiosis. With the assistance of gene editing techniques, both conventional and next-generation  
 693 probiotics may address many health-related concerns in the future. Given the increasing use of synthetic materials,  
 694 further research is necessary to fully understand the harm that microplastics pose to human health and the  
 695 environment, as well as to facilitate their complete eradication through cutting-edge gene editing technologies.

## 696 **SEARCH STRATEGY**

697 A systematic literature search was conducted to identify the harmful effects of MPs on the gut pollutants.  
 698 All relevant studies focusing on plastic disposal, the conversion of plastic to microplastic, metal accumulation on  
 699 their surface, their entry into the body, initiation of metal-induced gut dysbiosis, and neurodegeneration were  
 700 included. The search strategy utilized electronic databases, including PubMed, Scopus, Web of Science, and Google  
 701 Scholar. Various combinations of keywords related to plastic pollution, plastic to microplastic conversion, metal  
 702 accumulation, metal entry, MP entry, health issues due to metal administration and MP exposure, signaling  
 703 cascades, inflammation, cellular and neuronal stress, gut dysbiosis, neurodegeneration, probiotics as therapeutics,  
 704 probiotics as personalized medicine, probiotics side effects, and Parkinson's disease were used as search terms.  
 705 Additionally, reference lists of relevant articles and reviews were manually searched to identify additional studies.  
 706 This study included original research articles, review articles, and meta-analyses published in English without  
 707 restrictions on the publication date. Experimental studies, clinical trials, and observational studies investigating the  
 708 therapeutic roles of probiotics for metal toxicity, neuronal disease and altered gut microorganisms were also  
 709 considered. Exclusion criteria comprised studies not directly related to the topic, duplicate publications, conference  
 710 abstracts, editorials, and commentaries. The selection process involved screening initial search results based on  
 711 relevance, followed by a full-text assessment for eligibility. Data from selected studies were systematically  
 712 extracted, including study design, metal accumulation on MP surface, signaling cascades due to metal imbalance,  
 713 probiotics control on the gut-brain, gut-liver, gut-lung, gut-skin, hypothalamic-pituitary-adrenal, hypothalamic-  
 714 pituitary-thyroid, and hypothalamic-pituitary-gonadal axis, experimental or clinical outcomes with conventional and  
 715 nonconventional isolates, probiotics implications for controlling neurodegeneration, and molecular tools to improve  
 716 probiotics efficiency. Synthesized data were thematically organized to provide a comprehensive overview of the  
 717 harmful effects of MPs, their mode of interactions, stress induction, altered gut, neurodegeneration, and therapeutic  
 718 application of probiotics, contributing to a deeper understanding of the complex regulatory networks involved in  
 719 metal-induced gut dysbiosis.

## 720 **DECLARATIONS**

## 721 **ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

722 Not applicable

## 723 **CONSENT FOR PUBLICATION**

724 Not applicable

## 725 **AVAILABILITY OF DATA AND MATERIALS**

726 All data generated or analyzed during this study are included in this published article.

Question	Response
Data Availability	No

Sharing research data helps other researchers evaluate your findings, build on your work and to increase trust in your article. We encourage all our authors to make as much of their data publicly available as reasonably possible. Please note that your response to the following questions regarding the public data availability and the reasons for potentially not making data available will be available alongside your article upon publication.

Has data associated with your study been deposited into a publicly available repository?

Please select why. Please note that this statement will be available alongside your article upon publication. as follow-up to " **Data Availability**

Sharing research data helps other researchers evaluate your findings, build on your work and to increase trust in your article. We encourage all our authors to make as much of their data publicly available as reasonably possible. Please note that your response to the following questions regarding the public data availability and the reasons for potentially not making data available will be available alongside your article upon publication. Data will be made available on request

Has data associated with your study been deposited into a publicly available repository?

"

727

728 **SUPPLEMENTARY DATA**

729 There is no separate file for supplementary data

730 **COMPETING INTERESTS**

731 The authors declare that they have no competing interests

732 **FUNDING**

733 This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit  
734 sectors.

735 **AUTHORS' CONTRIBUTIONS**



736 IP is responsible for conceptualization, validation, writing and editing and SU is responsible for writing, drawing  
737 and editing. Both the authors were critically revised the manuscript concerning intellectual content and approved the  
738 final manuscript

## 739 ACKNOWLEDGEMENT

740 We express our gratitude to the Saveetha School of Engineering, Saveetha Institute of Medical and Technical  
741 Sciences, Saveetha University, for providing the necessary infrastructure to carry out this work successfully.

## 742 REFERENCES

- 743 [1] R.C. Thompson, Y. Olson, R.P. Mitchell, A. Davis, S.J. Rowland, A.W.G. John, D. McGonigle,  
744 A.E. Russell, Lost at Sea: Where Is All the Plastic?, *Science* (80-. ). 304 (2004) 838.  
745 <https://doi.org/10.1126/science.1094559>.
- 746 [2] T.C. Moulin, L.T. van Egmond, A possible role for pollutants in mental disorders via gut  
747 microbiota, *Sci. Total Environ.* 693 (2019) 133639.  
748 <https://doi.org/10.1016/j.scitotenv.2019.133639>.
- 749 [3] C.M. Rochman, E. Hoh, T. Kurobe, S.J. Teh, Ingested plastic transfers hazardous chemicals to fish  
750 and induces hepatic stress, *Sci. Rep.* 3 (2013) 1–7. <https://doi.org/10.1038/srep03263>.
- 751 [4] S. Rist, B. Carney Almroth, N.B. Hartmann, T.M. Karlsson, A critical perspective on early  
752 communications concerning human health aspects of microplastics, *Sci. Total Environ.* 626 (2018)  
753 720–726. <https://doi.org/10.1016/j.scitotenv.2018.01.092>.
- 754 [5] A.L. Andrady, Microplastics in the marine environment, *Mar. Pollut. Bull.* 62 (2011) 1596–1605.  
755 <https://doi.org/10.1016/j.marpolbul.2011.05.030>.
- 756 [6] A.L. Andrady, M.A. Neal, Applications and societal benefits of plastics, *Philos. Trans. R. Soc. B*  
757 *Biol. Sci.* 364 (2009) 1977–1984. <https://doi.org/10.1098/rstb.2008.0304>.
- 758 [7] A. Mehta, A. Mishra, S. Basu, N.P. Shetti, K.R. Reddy, T.A. Saleh, T.M. Aminabhavi, Band gap  
759 tuning and surface modification of carbon dots for sustainable environmental remediation and  
760 photocatalytic hydrogen production – A review, *J. Environ. Manage.* 250 (2019).  
761 <https://doi.org/10.1016/j.jenvman.2019.109486>.
- 762 [8] R.K. Srivastava, N.P. Shetti, K.R. Reddy, T.M. Aminabhavi, Sustainable energy from waste  
763 organic matters via efficient microbial processes, *Sci. Total Environ.* 722 (2020) 137927.  
764 <https://doi.org/10.1016/j.scitotenv.2020.137927>.
- 765 [9] S. Sharma, S. Basu, N.P. Shetti, T.M. Aminabhavi, Waste-to-energy nexus for circular economy  
766 and environmental protection: Recent trends in hydrogen energy, *Sci. Total Environ.* 713 (2020)  
767 136633. <https://doi.org/10.1016/j.scitotenv.2020.136633>.
- 768 [10] S. Sharma, S. Basu, N.P. Shetti, M.N. Nadagouda, T.M. Aminabhavi, Microplastics in the  
769 environment: Occurrence, perils, and eradication, *Chem. Eng. J.* 408 (2021) 127317.  
770 <https://doi.org/10.1016/j.cej.2020.127317>.
- 771 [11] J. Zhang, D. Gao, Q. Li, Y. Zhao, L. Li, H. Lin, Q. Bi, Y. Zhao, Biodegradation of polyethylene  
772 microplastic particles by the fungus *Aspergillus flavus* from the guts of wax moth *Galleria*  
773 *mellonella*, *Sci. Total Environ.* 704 (2020). <https://doi.org/10.1016/j.scitotenv.2019.135931>.

- 774 [12] Z. Sobhani, Y. Lei, Y. Tang, L. Wu, X. Zhang, R. Naidu, M. Megharaj, C. Fang, Microplastics  
775 generated when opening plastic packaging, *Sci. Rep.* 10 (2020) 1–7.  
776 <https://doi.org/10.1038/s41598-020-61146-4>.
- 777 [13] Y.L. Wang, Y.H. Lee, Y.H. Hsu, I.J. Chiu, C.C.Y. Huang, C.C. Huang, Z.C. Chia, C.P. Lee, Y.F.  
778 Lin, H.W. Chiu, The kidney-related effects of polystyrene microplastics on human kidney  
779 proximal tubular epithelial cells hk-2 and male c57bl/6 mice, *Environ. Health Perspect.* 129 (2021)  
780 1–18. <https://doi.org/10.1289/EHP7612>.
- 781 [14] K. Zhang, A.H. Hamidian, A. Tubić, Y. Zhang, J.K.H. Fang, C. Wu, P.K.S. Lam, Understanding  
782 plastic degradation and microplastic formation in the environment: A review, *Environ. Pollut.* 274  
783 (2021). <https://doi.org/10.1016/j.envpol.2021.116554>.
- 784 [15] V.M. Pathak, Navneet, Review on the current status of polymer degradation: a microbial  
785 approach, *Bioresour. Bioprocess.* 4 (2017). <https://doi.org/10.1186/s40643-017-0145-9>.
- 786 [16] H.S. Auta, C.U. Emenike, S.H. Fauziah, Distribution and importance of microplastics in the  
787 marine environment: A review of the sources, fate, effects, and potential solutions, *Environ. Int.*  
788 102 (2017) 165–176. <https://doi.org/https://doi.org/10.1016/j.envint.2017.02.013>.
- 789 [17] M. Shen, Y. Zhang, Y. Zhu, B. Song, G. Zeng, D. Hu, X. Wen, X. Ren, Recent advances in  
790 toxicological research of nanoplastics in the environment: A review, *Environ. Pollut.* 252 (2019)  
791 511–521. <https://doi.org/https://doi.org/10.1016/j.envpol.2019.05.102>.
- 792 [18] J. Yuan, J. Ma, Y. Sun, T. Zhou, Y. Zhao, F. Yu, Microbial degradation and other environmental  
793 aspects of microplastics/plastics, *Sci. Total Environ.* 715 (2020) 136968.  
794 <https://doi.org/https://doi.org/10.1016/j.scitotenv.2020.136968>.
- 795 [19] Z. Li, Y. Liu, D. Zhang, L. Feng, X. He, X. Duan, X. Li, H. Xie, Distribution and environmental  
796 risk assessment of microplastics in continental shelf sediments in the southern East China Sea: A  
797 high-spatial-resolution survey, *Mar. Pollut. Bull.* 177 (2022) 113548.  
798 <https://doi.org/https://doi.org/10.1016/j.marpolbul.2022.113548>.
- 799 [20] U. Anand, S. Dey, E. Bontempi, S. Ducoli, A.D. Vethaak, A. Dey, S. Federici, Biotechnological  
800 methods to remove microplastics: a review, *Environ. Chem. Lett.* 21 (2023) 1787–1810.  
801 <https://doi.org/10.1007/s10311-022-01552-4>.
- 802 [21] T. Thiounn, R.C. Smith, Advances and approaches for chemical recycling of plastic waste, *J.*  
803 *Polym. Sci.* 58 (2020) 1347–1364. <https://doi.org/10.1002/pol.20190261>.
- 804 [22] P.R. Sutkar, R.D. Gadewar, V.P. Dhulap, Recent trends in degradation of microplastics in the  
805 environment: A state-of-the-art review, *J. Hazard. Mater. Adv.* 11 (2023) 100343.  
806 <https://doi.org/10.1016/j.hazadv.2023.100343>.
- 807 [23] M. Padervand, E. Lichtfouse, D. Robert, C. Wang, Removal of microplastics from the  
808 environment. A review, *Environ. Chem. Lett.* 18 (2020) 807–828. <https://doi.org/10.1007/s10311-020-00983-1>.
- 810 [24] A.-U.-R. Bacha, I. Nabi, L. Zhang, Mechanisms and the Engineering Approaches for the  
811 Degradation of Microplastics, *ACS ES&T Eng.* 1 (2021) 1481–1501.  
812 <https://doi.org/10.1021/acsestengg.1c00216>.
- 813 [25] S.S. Ali, T. Elsamahy, E. Koutra, M. Kornaros, M. El-Sheekh, E.A. Abdelkarim, D. Zhu, J. Sun,

- 814 Degradation of conventional plastic wastes in the environment: A review on current status of  
815 knowledge and future perspectives of disposal, *Sci. Total Environ.* 771 (2021) 144719.  
816 <https://doi.org/10.1016/j.scitotenv.2020.144719>.
- 817 [26] P. Sarmah, J. Rout, Efficient biodegradation of low-density polyethylene by cyanobacteria isolated  
818 from submerged polyethylene surface in domestic sewage water, *Environ. Sci. Pollut. Res.* 25  
819 (2018) 33508–33520. <https://doi.org/10.1007/s11356-018-3079-7>.
- 820 [27] M. Schwartz, T. Perrot, E. Aubert, S. Dumarçay, F. Favier, P. Gérardin, M. Morel-Rouhier, G.  
821 Mulliert, F. Saiag, C. Didierjean, E. Gelhaye, Molecular recognition of wood polyphenols by  
822 phase II detoxification enzymes of the white rot *Trametes versicolor*, *Sci. Rep.* 8 (2018) 8472.  
823 <https://doi.org/10.1038/s41598-018-26601-3>.
- 824 [28] J. Shin, J.-E. Kim, Y.-W. Lee, H. Son, Fungal Cytochrome P450s and the P450 Complement  
825 (CYPome) of *Fusarium graminearum*, *Toxins (Basel)*. 10 (2018) 112.  
826 <https://doi.org/10.3390/toxins10030112>.
- 827 [29] N.A. Sacco, F.M. Zoppas, A. Devard, M. del P. González Muñoz, G. García, F.A. Marchesini,  
828 Recent Advances in Microplastics Removal from Water with Special Attention Given to  
829 Photocatalytic Degradation: Review of Scientific Research, *Microplastics* 2 (2023) 278–303.  
830 <https://doi.org/10.3390/microplastics2030023>.
- 831 [30] I. Pan, S. Umopathy, P.K. Issac, M.M. Rahman, A. Guru, J. Arockiaraj, The bioaccessibility of  
832 adsorped heavy metals on biofilm-coated microplastics and their implication for the progression of  
833 neurodegenerative diseases, *Environ. Monit. Assess.* 195 (2023) 1264.  
834 <https://doi.org/10.1007/s10661-023-11890-7>.
- 835 [31] X. Guo, J. Wang, Sorption of antibiotics onto aged microplastics in freshwater and seawater, *Mar.*  
836 *Pollut. Bull.* 149 (2019) 110511. <https://doi.org/10.1016/j.marpolbul.2019.110511>.
- 837 [32] G. Liu, Z. Zhu, Y. Yang, Y. Sun, F. Yu, J. Ma, Sorption behavior and mechanism of hydrophilic  
838 organic chemicals to virgin and aged microplastics in freshwater and seawater, *Environ. Pollut.*  
839 246 (2019) 26–33. <https://doi.org/10.1016/j.envpol.2018.11.100>.
- 840 [33] M. Cole, P. Lindeque, C. Halsband, T.S. Galloway, Microplastics as contaminants in the marine  
841 environment: A review, *Mar. Pollut. Bull.* 62 (2011) 2588–2597.  
842 <https://doi.org/https://doi.org/10.1016/j.marpolbul.2011.09.025>.
- 843 [34] J.C. Prata, J.P. da Costa, I. Lopes, A.C. Duarte, T. Rocha-Santos, Environmental exposure to  
844 microplastics: An overview on possible human health effects, *Sci. Total Environ.* 702 (2020)  
845 134455. <https://doi.org/10.1016/j.scitotenv.2019.134455>.
- 846 [35] M. Cole, P. Lindeque, E. Fileman, C. Halsband, R. Goodhead, J. Moger, T.S. Galloway,  
847 Microplastic ingestion by zooplankton, *Environ. Sci. Technol.* 47 (2013) 6646–6655.  
848 <https://doi.org/10.1021/es400663f>.
- 849 [36] N. Seng, S. Lai, J. Fong, M.F. Saleh, C. Cheng, Z.Y. Cheok, P.A. Todd, Early evidence of  
850 microplastics on seagrass and macroalgae, *Mar. Freshw. Res.* 71 (2020) 922–928.  
851 <https://doi.org/10.1071/MF19177>.
- 852 [37] C. Sun, Z. Wang, L. Chen, F. Li, Fabrication of robust and compressive chitin and graphene oxide  
853 sponges for removal of microplastics with different functional groups, *Chem. Eng. J.* 393 (2020)  
854 124796. <https://doi.org/10.1016/j.cej.2020.124796>.

- 855 [38] P. Kolandhasamy, L. Su, J. Li, X. Qu, K. Jabeen, H. Shi, Adherence of microplastics to soft tissue  
856 of mussels: A novel way to uptake microplastics beyond ingestion, *Sci. Total Environ.* 610–611  
857 (2018) 635–640. <https://doi.org/https://doi.org/10.1016/j.scitotenv.2017.08.053>.
- 858 [39] A.R. McGoran, P.F. Clark, B.D. Smith, D. Morrith, High prevalence of plastic ingestion by  
859 *Eriocheir sinensis* and *Carcinus maenas* (Crustacea: Decapoda: Brachyura) in the Thames Estuary,  
860 *Environ. Pollut.* 265 (2020) 114972. <https://doi.org/https://doi.org/10.1016/j.envpol.2020.114972>.
- 861 [40] T.A. Plee, C.M. Pomory, Microplastics in sandy environments in the Florida Keys and the  
862 panhandle of Florida, and the ingestion by sea cucumbers (Echinodermata: Holothuroidea) and  
863 sand dollars (Echinodermata: Echinoidea)., *Mar. Pollut. Bull.* 158 (2020) 111437.  
864 <https://doi.org/10.1016/j.marpolbul.2020.111437>.
- 865 [41] S. Rezania, J. Park, M.F. Md Din, S. Mat Taib, A. Talaiekhozani, K. Kumar Yadav, H. Kamyab,  
866 Microplastics pollution in different aquatic environments and biota: A review of recent studies,  
867 *Mar. Pollut. Bull.* 133 (2018) 191–208. <https://doi.org/10.1016/j.marpolbul.2018.05.022>.
- 868 [42] S.L. Wright, R.C. Thompson, T.S. Galloway, The physical impacts of microplastics on marine  
869 organisms: A review, *Environ. Pollut.* 178 (2013) 483–492.  
870 <https://doi.org/https://doi.org/10.1016/j.envpol.2013.02.031>.
- 871 [43] R. Sussarellu, M. Suquet, Y. Thomas, C. Lambert, C. Fabioux, M.E.J. Pernet, N. Le Goïc, V.  
872 Quillien, C. Mingant, Y. Epelboin, C. Corporeau, J. Guyomarch, J. Robbens, I. Paul-Pont, P.  
873 Soudant, A. Huvet, Oyster reproduction is affected by exposure to polystyrene microplastics.,  
874 *Proc. Natl. Acad. Sci. U. S. A.* 113 (2016) 2430–2435. <https://doi.org/10.1073/pnas.1519019113>.
- 875 [44] A. Gkrillas, H. Dirven, M. Andreassen, E. Papadopoulou, H. Hjertholm, T. Husøy, Risk  
876 assessment of phthalates based on aggregated exposure from foods and personal care products  
877 and comparison with biomonitoring data., *EFSA Journal. Eur. Food Saf. Auth.* 18 (2020) e181105.  
878 <https://doi.org/10.2903/j.efsa.2020.e181105>.
- 879 [45] R.G. Poston, R.N. Saha, Epigenetic effects of polybrominated diphenyl ethers on human health,  
880 *Int. J. Environ. Res. Public Health* 16 (2019). <https://doi.org/10.3390/ijerph16152703>.
- 881 [46] S. Abbasi, A. Turner, Human exposure to microplastics: A study in Iran., *J. Hazard. Mater.* 403  
882 (2021) 123799. <https://doi.org/10.1016/j.jhazmat.2020.123799>.
- 883 [47] A. Ragusa, A. Svelato, C. Santacroce, P. Catalano, V. Notarstefano, O. Carnevali, F. Papa, M.C.A.  
884 Rongioletti, F. Baiocco, S. Draghi, E. D'Amore, D. Rinaldo, M. Matta, E. Giorgini, Plasticenta:  
885 First evidence of microplastics in human placenta, *Environ. Int.* 146 (2021) 106274.  
886 <https://doi.org/https://doi.org/10.1016/j.envint.2020.106274>.
- 887 [48] T. Braun, L. Ehrlich, W. Henrich, S. Koepfel, I. Lomako, P. Schwabl, B. Liebmann, Detection of  
888 Microplastic in Human Placenta and Meconium in a Clinical Setting., *Pharmaceutics* 13 (2021).  
889 <https://doi.org/10.3390/pharmaceutics13070921>.
- 890 [49] L.F. Amato-Lourenço, R. Carvalho-Oliveira, G.R. Júnior, L. Dos Santos Galvão, R.A. Ando, T.  
891 Mauad, Presence of airborne microplastics in human lung tissue., *J. Hazard. Mater.* 416 (2021)  
892 126124. <https://doi.org/10.1016/j.jhazmat.2021.126124>.
- 893 [50] L.C. Jenner, J.M. Rotchell, R.T. Bennett, M. Cowen, V. Tentzeris, L.R. Sadofsky, Detection of  
894 microplastics in human lung tissue using  $\mu$ FTIR spectroscopy, *Sci. Total Environ.* 831 (2022)  
895 154907. <https://doi.org/https://doi.org/10.1016/j.scitotenv.2022.154907>.

- 896 [51] A. Luqman, H. Nugrahapraja, R.A. Wahyuono, I. Islami, M.H. Haekal, Y. Fardiansyah, B.Q.  
897 Putri, F.I. Amalludin, E.A. Rofiqqa, F. Götz, A.T. Wibowo, Microplastic contamination in human  
898 stools, foods, and drinking water associated with Indonesian coastal population, *Environ. - MDPI*  
899 8 (2021) 1–9. <https://doi.org/10.3390/environments8120138>.
- 900 [52] A.T. Wibowo, H. Nugrahapraja, R.A. Wahyuono, I. Islami, M.H. Haekal, Y. Fardiansyah, P.W.W.  
901 Sugiyo, Y.K. Putro, F.N. Fauzia, H. Santoso, F. Götz, B.V. Tangahu, A. Luqman, Microplastic  
902 contamination in the human gastrointestinal tract and daily consumables associated with an  
903 Indonesian farming community, *Sustain.* 13 (2021). <https://doi.org/10.3390/su132212840>.
- 904 [53] A. Ragusa, V. Notarstefano, A. Svelato, A. Belloni, G. Gioacchini, C. Blondeel, E. Zucchelli, C.  
905 De Luca, S. D'Avino, A. Gulotta, O. Carnevali, E. Giorgini, Raman Microspectroscopy Detection  
906 and Characterisation of Microplastics in Human Breastmilk., *Polymers (Basel)*. 14 (2022).  
907 <https://doi.org/10.3390/polym14132700>.
- 908 [54] H. Nugrahapraja, P.W.W. Sugiyo, B.Q. Putri, Ni'matuzahroh, Fatimah, L. Huang, N. Hafza, F.  
909 Götz, H. Santoso, A.T. Wibowo, A. Luqman, Effects of Microplastic on Human Gut Microbiome:  
910 Detection of Plastic-Degrading Genes in Human Gut Exposed to Microplastics—Preliminary  
911 Study, *Environ. - MDPI* 9 (2022). <https://doi.org/10.3390/environments9110140>.
- 912 [55] J.Y. Yoo, M. Groer, S.V.O. Dutra, A. Sarkar, D.I. McSkimming, Gut Microbiota and Immune  
913 System Interactions., *Microorganisms* 8 (2020). <https://doi.org/10.3390/microorganisms8101587>.
- 914 [56] D. Dupont, Food structure affects the kinetics of food digestion and the bioavailability of nutrients,  
915 *Hal.Archives-Ouvertes.Fr* (2020).
- 916 [57] A. Tamargo, N. Molinero, J.J. Reinoso, V. Alcolea-Rodriguez, R. Portela, M.A. Bañares, J.F.  
917 Fernández, M.V. Moreno-Arribas, PET microplastics affect human gut microbiota communities  
918 during simulated gastrointestinal digestion, first evidence of plausible polymer biodegradation  
919 during human digestion, *Sci. Rep.* 12 (2022) 1–15. <https://doi.org/10.1038/s41598-021-04489-w>.
- 920 [58] A. Mackie, A.I. Mulet-Cabero, A. Torcello-Gomez, Simulating human digestion: Developing our  
921 knowledge to create healthier and more sustainable foods, *Food Funct.* 11 (2020) 9397–9431.  
922 <https://doi.org/10.1039/d0fo01981j>.
- 923 [59] I. Pan, P.K. Issac, M.M. Rahman, A. Guru, J. Arockiaraj, Gut-Brain Axis a Key Player to Control  
924 Gut Dysbiosis in Neurological Diseases, *Mol. Neurobiol.* (2023). <https://doi.org/10.1007/s12035-023-03691-3>.
- 926 [60] M. Carabotti, A. Scirocco, M.A. Maselli, C. Severi, The gut-brain axis: Interactions between  
927 enteric microbiota, central and enteric nervous systems, *Ann. Gastroenterol.* 28 (2015) 203–209.
- 928 [61] W. Grodzicki, K. Dziendzikowska, J. Gromadzka-Ostrowska, M. Kruszewski, Nanoplastic impact  
929 on the gut-brain axis: Current knowledge and future directions, *Int. J. Mol. Sci.* 22 (2021).  
930 <https://doi.org/10.3390/ijms222312795>.
- 931 [62] J.F. Cryan, K.J. O'riordan, C.S.M. Cowan, K. V. Sandhu, T.F.S. Bastiaanssen, M. Boehme, M.G.  
932 Codagnone, S. Cusotto, C. Fulling, A. V. Golubeva, K.E. Guzzetta, M. Jaggar, C.M. Long-Smith,  
933 J.M. Lyte, J.A. Martin, A. Molinero-Perez, G. Moloney, E. Morelli, E. Morillas, R. O'connor, J.S.  
934 Cruz-Pereira, V.L. Peterson, K. Rea, N.L. Ritz, E. Sherwin, S. Spichak, E.M. Teichman, M. van  
935 de Wouw, A.P. Ventura-Silva, S.E. Wallace-Fitzsimons, N. Hyland, G. Clarke, T.G. Dinan, The  
936 microbiota-gut-brain axis, *Physiol. Rev.* 99 (2019) 1877–2013.  
937 <https://doi.org/10.1152/physrev.00018.2018>.

- 938 [63] L.H. Morais, H.L. Schreiber, S.K. Mazmanian, The gut microbiota–brain axis in behaviour and  
939 brain disorders, *Nat. Rev. Microbiol.* 19 (2021) 241–255. [https://doi.org/10.1038/s41579-020-](https://doi.org/10.1038/s41579-020-00460-0)  
940 00460-0.
- 941 [64] C. Campanale, C. Massarelli, I. Savino, V. Locaputo, V.F. Uricchio, A detailed review study on  
942 potential effects of microplastics and additives of concern on human health, *Int. J. Environ. Res.*  
943 *Public Health* 17 (2020). <https://doi.org/10.3390/ijerph17041212>.
- 944 [65] M. Pirsaeheb, H. Hossini, P. Makhdoumi, Review of microplastic occurrence and toxicological  
945 effects in marine environment: Experimental evidence of inflammation, *Process Saf. Environ.*  
946 *Prot.* 142 (2020) 1–14. <https://doi.org/10.1016/j.psep.2020.05.050>.
- 947 [66] C.D. Rummel, A. Jahnke, E. Gorokhova, D. Kühnel, M. Schmitt-Jansen, Impacts of biofilm  
948 formation on the fate and potential effects of microplastic in the aquatic environment, *Environ.*  
949 *Sci. Technol. Lett.* 4 (2017) 258–267. <https://doi.org/10.1021/acs.estlett.7b00164>.
- 950 [67] A.I. Catarino, V. Macchia, W.G. Sanderson, R.C. Thompson, T.B. Henry, Low levels of  
951 microplastics (MP) in wild mussels indicate that MP ingestion by humans is minimal compared to  
952 exposure via household fibres fallout during a meal, *Environ. Pollut.* 237 (2018) 675–684.  
953 <https://doi.org/https://doi.org/10.1016/j.envpol.2018.02.069>.
- 954 [68] J.G.B. Derraik, The pollution of the marine environment by plastic debris: a review, *Mar. Pollut.*  
955 *Bull.* 44 (2002) 842–852. [https://doi.org/https://doi.org/10.1016/S0025-326X\(02\)00220-5](https://doi.org/https://doi.org/10.1016/S0025-326X(02)00220-5).
- 956 [69] M. Cole, P. Lindeque, E. Fileman, C. Halsband, T.S. Galloway, The impact of polystyrene  
957 microplastics on feeding, function and fecundity in the marine copepod *Calanus helgolandicus*,  
958 *Environ. Sci. Technol.* 49 (2015) 1130–1137. <https://doi.org/10.1021/es504525u>.
- 959 [70] N.A.C. Welden, P.R. Cowie, Environment and gut morphology influence microplastic retention in  
960 langoustine, *Nephrops norvegicus*, *Environ. Pollut.* 214 (2016) 859–865.  
961 <https://doi.org/https://doi.org/10.1016/j.envpol.2016.03.067>.
- 962 [71] P. Celi, A.J. Cowieson, F. Fru-Nji, R.E. Steinert, A.-M. Klünter, V. Verlhac, Gastrointestinal  
963 functionality in animal nutrition and health: New opportunities for sustainable animal production,  
964 *Anim. Feed Sci. Technol.* 234 (2017) 88–100.  
965 <https://doi.org/https://doi.org/10.1016/j.anifeedsci.2017.09.012>.
- 966 [72] E. Ringø, Z. Zhou, J.L.G. Vecino, S. Wadsworth, J. Romero, Krogdahl, R.E. Olsen, A.  
967 Dimitroglou, A. Foey, S. Davies, M. Owen, H.L. Lauzon, L.L. Martinsen, P. De Schryver, P.  
968 Bossier, S. Sperstad, D.L. Merrifield, Effect of dietary components on the gut microbiota of  
969 aquatic animals. A never-ending story?, *Aquac. Nutr.* 22 (2016) 219–282.  
970 <https://doi.org/10.1111/anu.12346>.
- 971 [73] S. Egerton, S. Culloty, J. Whooley, C. Stanton, R.P. Ross, The Gut Microbiota of Marine Fish.,  
972 *Front. Microbiol.* 9 (2018) 873. <https://doi.org/10.3389/fmicb.2018.00873>.
- 973 [74] T. Pérez, J.L. Balcázar, I. Ruiz-Zarzuola, N. Halaihel, D. Vendrell, I. de Blas, J.L. Múzquiz, Host–  
974 microbiota interactions within the fish intestinal ecosystem, *Mucosal Immunol.* 3 (2010) 355–360.  
975 <https://doi.org/https://doi.org/10.1038/mi.2010.12>.
- 976 [75] C.A. Gaulke, C.L. Barton, S. Proffitt, R.L. Tanguay, T.J. Sharpton, Triclosan exposure is  
977 associated with rapid restructuring of the microbiome in adult zebrafish, *PLoS One* 11 (2016) 1–  
978 20. <https://doi.org/10.1371/journal.pone.0154632>.

- 979 [76] G.A. Weiss, T. Hennet, Mechanisms and consequences of intestinal dysbiosis, *Cell. Mol. Life Sci.*  
980 74 (2017) 2959–2977. <https://doi.org/10.1007/s00018-017-2509-x>.
- 981 [77] J. Li, S. Thamphiwatana, W. Liu, B. Esteban-Fernández de Ávila, P. Angsantikul, E. Sandraz, J.  
982 Wang, T. Xu, F. Soto, V. Ramez, X. Wang, W. Gao, L. Zhang, J. Wang, Enteric Micromotor Can  
983 Selectively Position and Spontaneously Propel in the Gastrointestinal Tract., *ACS Nano* 10 (2016)  
984 9536–9542. <https://doi.org/10.1021/acsnano.6b04795>.
- 985 [78] M. Yan, W. Li, X. Chen, Y. He, X. Zhang, H. Gong, A preliminary study of the association  
986 between colonization of microorganism on microplastics and intestinal microbiota in shrimp under  
987 natural conditions, *J. Hazard. Mater.* 408 (2021) 124882.  
988 <https://doi.org/https://doi.org/10.1016/j.jhazmat.2020.124882>.
- 989 [79] S.P. Claus, H. Guillou, S. Ellero-Simatos, The gut microbiota: a major player in the toxicity of  
990 environmental pollutants?, *NPJ Biofilms Microbiomes* 2 (2016) 16003.  
991 <https://doi.org/10.1038/npjbiofilms.2016.3>.
- 992 [80] A. Heintz-Buschart, P. Wilmes, Human Gut Microbiome: Function Matters., *Trends Microbiol.* 26  
993 (2018) 563–574. <https://doi.org/10.1016/j.tim.2017.11.002>.
- 994 [81] K.H. Collins, D.J. Schwartz, K.L. Lenz, C.A. Harris, F. Guilak, Taxonomic changes in the gut  
995 microbiota are associated with cartilage damage independent of adiposity, high fat diet, and joint  
996 injury, *Sci. Rep.* 11 (2021) 1–7. <https://doi.org/10.1038/s41598-021-94125-4>.
- 997 [82] L. Liu, K. Xu, B. Zhang, Y. Ye, Q. Zhang, W. Jiang, Cellular internalization and release of  
998 polystyrene microplastics and nanoplastics, *Sci. Total Environ.* 779 (2021) 146523.  
999 <https://doi.org/10.1016/j.scitotenv.2021.146523>.
- 1000 [83] D. Choi, J. Hwang, J. Bang, S. Han, T. Kim, Y. Oh, Y. Hwang, J. Choi, J. Hong, In vitro toxicity  
1001 from a physical perspective of polyethylene microplastics based on statistical curvature change  
1002 analysis, *Sci. Total Environ.* 752 (2021) 142242. <https://doi.org/10.1016/j.scitotenv.2020.142242>.
- 1003 [84] J.B. Fleury, V.A. Baulin, Microplastics destabilize lipid membranes by mechanical stretching,  
1004 *Proc. Natl. Acad. Sci. U. S. A.* 118 (2021) 1–8. <https://doi.org/10.1073/pnas.2104610118>.
- 1005 [85] Q. Wang, Y. Wu, W. Zhang, T. Shen, H. Li, J. Wu, L. Zhang, L. Qin, R. Chen, W. Gu, Q. Sun, C.  
1006 Liu, R. Li, Lipidomics and transcriptomics insight into impacts of microplastics exposure on  
1007 hepatic lipid metabolism in mice, *Chemosphere* 308 (2022) 136591.  
1008 <https://doi.org/https://doi.org/10.1016/j.chemosphere.2022.136591>.
- 1009 [86] A. Salimi, A. Alavehzadeh, M. Ramezani, J. Pourahmad, Differences in sensitivity of human  
1010 lymphocytes and fish lymphocytes to polyvinyl chloride microplastic toxicity, *Toxicol. Ind.*  
1011 *Health* 38 (2022) 100–111. <https://doi.org/10.1177/07482337211065832>.
- 1012 [87] S. Li, Y. Ma, S. Ye, S. Tang, N. Liang, Y. Liang, F. Xiao, Polystyrene microplastics trigger  
1013 hepatocyte apoptosis and abnormal glycolytic flux via ROS-driven calcium overload, *J. Hazard.*  
1014 *Mater.* 417 (2021) 126025. <https://doi.org/https://doi.org/10.1016/j.jhazmat.2021.126025>.
- 1015 [88] Y. Wang, Z. Mao, M. Zhang, G. Ding, J. Sun, M. Du, Q. Liu, Y. Cong, F. Jin, W. Zhang, J. Wang,  
1016 The uptake and elimination of polystyrene microplastics by the brine shrimp, *Artemia*  
1017 *parthenogenetica*, and its impact on its feeding behavior and intestinal histology, *Chemosphere*  
1018 234 (2019) 123–131. <https://doi.org/10.1016/j.chemosphere.2019.05.267>.

- 1019 [89] X. Jiang, Y. Chang, T. Zhang, Y. Qiao, G. Klobučar, M. Li, Toxicological effects of polystyrene  
1020 microplastics on earthworm (*Eisenia fetida*), *Environ. Pollut.* 259 (2020) 113896.  
1021 <https://doi.org/10.1016/j.envpol.2019.113896>.
- 1022 [90] E.E. Schneeberger, R.D. Lynch, The tight junction: A multifunctional complex, *Am. J. Physiol. -*  
1023 *Cell Physiol.* 286 (2004). <https://doi.org/10.1152/ajpcell.00558.2003>.
- 1024 [91] T. Luo, C. Wang, Z. Pan, C. Jin, Z. Fu, Y. Jin, Maternal Polystyrene Microplastic Exposure during  
1025 Gestation and Lactation Altered Metabolic Homeostasis in the Dams and Their F1 and F2  
1026 Offspring, *Environ. Sci. Technol.* 53 (2019) 10978–10992.  
1027 <https://doi.org/10.1021/acs.est.9b03191>.
- 1028 [92] W.S. Garrett, J.I. Gordon, L.H. Glimcher, Homeostasis and Inflammation in the Intestine, *Cell* 140  
1029 (2010) 859–870. <https://doi.org/10.1016/j.cell.2010.01.023>.
- 1030 [93] B. Singh, N. Sharma, Mechanistic implications of plastic degradation, *Polym. Degrad. Stab.* 93  
1031 (2008) 561–584. <https://doi.org/https://doi.org/10.1016/j.polymdegradstab.2007.11.008>.
- 1032 [94] G.C. Hansson, Role of mucus layers in gut infection and inflammation., *Curr. Opin. Microbiol.* 15  
1033 (2012) 57–62. <https://doi.org/10.1016/j.mib.2011.11.002>.
- 1034 [95] T. Pelaseyed, J.H. Bergström, J.K. Gustafsson, A. Ermund, G.M.H. Birchenough, A. Schütte, S.  
1035 van der Post, F. Svensson, A.M. Rodríguez-Piñeiro, E.E.L. Nyström, C. Wising, M.E. V  
1036 Johansson, G.C. Hansson, The mucus and mucins of the goblet cells and enterocytes provide the  
1037 first defense line of the gastrointestinal tract and interact with the immune system., *Immunol. Rev.*  
1038 260 (2014) 8–20. <https://doi.org/10.1111/imr.12182>.
- 1039 [96] M. Zhu, M. Chernick, D. Rittschof, D.E. Hinton, Chronic dietary exposure to polystyrene  
1040 microplastics in maturing Japanese medaka (*Oryzias latipes*), *Aquat. Toxicol.* 220 (2020) 105396.  
1041 <https://doi.org/https://doi.org/10.1016/j.aquatox.2019.105396>.
- 1042 [97] H.-M. Kang, E. Byeon, H. Jeong, M.-S. Kim, Q. Chen, J.-S. Lee, Different effects of nano- and  
1043 microplastics on oxidative status and gut microbiota in the marine medaka *Oryzias melastigma*, *J.*  
1044 *Hazard. Mater.* 405 (2021) 124207. <https://doi.org/https://doi.org/10.1016/j.jhazmat.2020.124207>.
- 1045 [98] J.-N. Huang, B. Wen, J.-G. Zhu, Y.-S. Zhang, J.-Z. Gao, Z.-Z. Chen, Exposure to microplastics  
1046 impairs digestive performance, stimulates immune response and induces microbiota dysbiosis in  
1047 the gut of juvenile guppy (*Poecilia reticulata*), *Sci. Total Environ.* 733 (2020) 138929.  
1048 <https://doi.org/https://doi.org/10.1016/j.scitotenv.2020.138929>.
- 1049 [99] H. Yang, H. Xiong, K. Mi, W. Xue, W. Wei, Y. Zhang, Toxicity comparison of nano-sized and  
1050 micron-sized microplastics to Goldfish *Carassius auratus* Larvae, *J. Hazard. Mater.* 388 (2020)  
1051 122058. <https://doi.org/https://doi.org/10.1016/j.jhazmat.2020.122058>.
- 1052 [100] G. Limonta, A. Mancina, A. Benkhalqui, C. Bertolucci, L. Abelli, M.C. Fossi, C. Pantì,  
1053 Microplastics induce transcriptional changes, immune response and behavioral alterations in adult  
1054 zebrafish, *Sci. Rep.* 9 (2019) 1–11. <https://doi.org/10.1038/s41598-019-52292-5>.
- 1055 [101] Y. Jin, L. Lu, W. Tu, T. Luo, Z. Fu, Impacts of polystyrene microplastic on the gut barrier,  
1056 microbiota and metabolism of mice, *Sci. Total Environ.* 649 (2019) 308–317.  
1057 <https://doi.org/https://doi.org/10.1016/j.scitotenv.2018.08.353>.
- 1058 [102] A. Dupont, L. Heinbockel, K. Brandenburg, M.W. Hornef, Antimicrobial peptides and the enteric



- 1059 mucus layer act in concert to protect the intestinal mucosa., *Gut Microbes* 5 (2014) 761–765.  
1060 <https://doi.org/10.4161/19490976.2014.972238>.
- 1061 [103] S. Mukherjee, L.V. Hooper, Antimicrobial Defense of the Intestine, *Immunity* 42 (2015) 28–39.  
1062 <https://doi.org/https://doi.org/10.1016/j.immuni.2014.12.028>.
- 1063 [104] A.F. Hofmann, L. Eckmann, How bile acids confer gut mucosal protection against bacteria., *Proc.*  
1064 *Natl. Acad. Sci. U. S. A.* 103 (2006) 4333–4334. <https://doi.org/10.1073/pnas.0600780103>.
- 1065 [105] R. Qiao, C. Sheng, Y. Lu, Y. Zhang, H. Ren, B. Lemos, Microplastics induce intestinal  
1066 inflammation, oxidative stress, and disorders of metabolome and microbiome in zebrafish, *Sci.*  
1067 *Total Environ.* 662 (2019) 246–253.  
1068 <https://doi.org/https://doi.org/10.1016/j.scitotenv.2019.01.245>.
- 1069 [106] B. Li, Y. Ding, X. Cheng, D. Sheng, Z. Xu, Q. Rong, Y. Wu, H. Zhao, X. Ji, Y. Zhang,  
1070 Polyethylene microplastics affect the distribution of gut microbiota and inflammation development  
1071 in mice, *Chemosphere* 244 (2020) 125492.  
1072 <https://doi.org/https://doi.org/10.1016/j.chemosphere.2019.125492>.
- 1073 [107] Y. Mu, J. Sun, Z. Li, W. Zhang, Z. Liu, C. Li, C. Peng, G. Cui, H. Shao, Z. Du, Activation of  
1074 pyroptosis and ferroptosis is involved in the hepatotoxicity induced by polystyrene microplastics  
1075 in mice, *Chemosphere* 291 (2022) 132944.  
1076 <https://doi.org/https://doi.org/10.1016/j.chemosphere.2021.132944>.
- 1077 [108] H. Gu, S. Wang, X. Wang, X. Yu, M. Hu, W. Huang, Y. Wang, Nanoplastics impair the intestinal  
1078 health of the juvenile large yellow croaker *Larimichthys crocea*, *J. Hazard. Mater.* 397 (2020)  
1079 122773. <https://doi.org/https://doi.org/10.1016/j.jhazmat.2020.122773>.
- 1080 [109] S. Amar, A. Binet, O. Tétéau, A. Desmarchais, P. Papillier, M.Z. Lacroix, V. Maillard, F. Guérif,  
1081 S. Elis, Bisphenol S Impaired Human Granulosa Cell Steroidogenesis in Vitro., *Int. J. Mol. Sci.* 21  
1082 (2020). <https://doi.org/10.3390/ijms21051821>.
- 1083 [110] E. Campioli, D.B. Martinez-Arguelles, V. Papadopoulos, In utero exposure to the endocrine  
1084 disruptor di-(2-ethylhexyl) phthalate promotes local adipose and systemic inflammation in adult  
1085 male offspring, *Nutr. Diabetes* 4 (2014) e115-10. <https://doi.org/10.1038/nutd.2014.13>.
- 1086 [111] R. Loretta, A. Sansone, M. Sansone, F. Romanelli, M. Appetecchia, Endocrine Disrupting  
1087 Chemicals: Effects on Endocrine Glands., *Front. Endocrinol. (Lausanne)*. 10 (2019) 178.  
1088 <https://doi.org/10.3389/fendo.2019.00178>.
- 1089 [112] J.B. Graceli, R.S. Dettogni, E. Merlo, O. Niño, C.S. da Costa, J.F. Zanol, E.A. Ríos Morris, L.  
1090 Miranda-Alves, A.C. Denicol, The impact of endocrine-disrupting chemical exposure in the  
1091 mammalian hypothalamic-pituitary axis, *Mol. Cell. Endocrinol.* 518 (2020) 110997.  
1092 <https://doi.org/https://doi.org/10.1016/j.mce.2020.110997>.
- 1093 [113] K. Kannan, K. Vimalkumar, A Review of Human Exposure to Microplastics and Insights Into  
1094 Microplastics as Obesogens., *Front. Endocrinol. (Lausanne)*. 12 (2021) 724989.  
1095 <https://doi.org/10.3389/fendo.2021.724989>.
- 1096 [114] F. Gallo, C. Fossi, R. Weber, D. Santillo, J. Sousa, I. Ingram, A. Nadal, D. Romano, Marine litter  
1097 plastics and microplastics and their toxic chemicals components: the need for urgent preventive  
1098 measures, *Environ. Sci. Eur.* 30 (2018). <https://doi.org/10.1186/s12302-018-0139-z>.

- 1099 [115] S. Ullah, S. Ahmad, X. Guo, S. Ullah, S. Ullah, G. Nabi, K. Wanghe, A review of the endocrine  
1100 disrupting effects of micro and nano plastic and their associated chemicals in mammals, *Front.*  
1101 *Endocrinol. (Lausanne)*. 13 (2023) 1–17. <https://doi.org/10.3389/fendo.2022.1084236>.
- 1102 [116] Q. Ma, P. Deng, M. Lin, L. Yang, L. Li, L. Guo, L. Zhang, M. He, Y. Lu, H. Pi, Y. Zhang, Z. Yu,  
1103 C. Chen, Z. Zhou, Long-term bisphenol A exposure exacerbates diet-induced prediabetes via  
1104 TLR4-dependent hypothalamic inflammation, *J. Hazard. Mater.* 402 (2021) 123926.  
1105 <https://doi.org/https://doi.org/10.1016/j.jhazmat.2020.123926>.
- 1106 [117] S.A. Ronchetti, G. V Novack, M.S. Bianchi, M.C. Crocco, B.H. Duvilanski, J.P. Cabilla, In vivo  
1107 xenoestrogenic actions of cadmium and arsenic in anterior pituitary and uterus., *Reproduction* 152  
1108 (2016) 1–10. <https://doi.org/10.1530/REP-16-0115>.
- 1109 [118] E.C. Plunk, S.M. Richards, Endocrine-Disrupting Air Pollutants and Their Effects on the  
1110 Hypothalamus-Pituitary-Gonadal Axis., *Int. J. Mol. Sci.* 21 (2020).  
1111 <https://doi.org/10.3390/ijms21239191>.
- 1112 [119] C.-Y. Deng, M. Lv, B.-H. Luo, S.-Z. Zhao, Z.-C. Mo, Y.-J. Xie, The Role of the  
1113 PI3K/AKT/mTOR Signalling Pathway in Male Reproduction., *Curr. Mol. Med.* 21 (2021) 539–  
1114 548. <https://doi.org/10.2174/1566524020666201203164910>.
- 1115 [120] H. Jin, T. Ma, X. Sha, Z. Liu, Y. Zhou, X. Meng, Y. Chen, X. Han, J. Ding, Polystyrene  
1116 microplastics induced male reproductive toxicity in mice, *J. Hazard. Mater.* 401 (2021) 123430.  
1117 <https://doi.org/https://doi.org/10.1016/j.jhazmat.2020.123430>.
- 1118 [121] B. Hou, F. Wang, T. Liu, Z. Wang, Reproductive toxicity of polystyrene microplastics: In vivo  
1119 experimental study on testicular toxicity in mice, *J. Hazard. Mater.* 405 (2021) 124028.  
1120 <https://doi.org/https://doi.org/10.1016/j.jhazmat.2020.124028>.
- 1121 [122] J. Tu, A.H.-H. Cheung, C.L.-K. Chan, W.-Y. Chan, The Role of microRNAs in Ovarian Granulosa  
1122 Cells in Health and Disease., *Front. Endocrinol. (Lausanne)*. 10 (2019) 174.  
1123 <https://doi.org/10.3389/fendo.2019.00174>.
- 1124 [123] R. An, X. Wang, L. Yang, J. Zhang, N. Wang, F. Xu, Y. Hou, H. Zhang, L. Zhang, Polystyrene  
1125 microplastics cause granulosa cells apoptosis and fibrosis in ovary through oxidative stress in  
1126 rats., *Toxicology* 449 (2021) 152665. <https://doi.org/10.1016/j.tox.2020.152665>.
- 1127 [124] C.B. Jeong, H.M. Kang, M.C. Lee, D.H. Kim, J. Han, D.S. Hwang, S. Souissi, S.J. Lee, K.H. Shin,  
1128 H.G. Park, J.S. Lee, Adverse effects of microplastics and oxidative stress-induced MAPK/Nrf2  
1129 pathway-mediated defense mechanisms in the marine copepod *Paracyclopsina nana*, *Sci. Rep.* 7  
1130 (2017) 1–11. <https://doi.org/10.1038/srep41323>.
- 1131 [125] W. Lin, R. Jiang, S. Hu, X. Xiao, J. Wu, S. Wei, Y. Xiong, G. Ouyang, Investigating the toxicities  
1132 of different functionalized polystyrene nanoplastics on *Daphnia magna*, *Ecotoxicol. Environ. Saf.*  
1133 180 (2019) 509–516. <https://doi.org/10.1016/j.ecoenv.2019.05.036>.
- 1134 [126] A.A. Souza Machado, W. Kloas, C. Zarfl, S. Hempel, M.C. Rillig, Microplastics as an emerging  
1135 threat to terrestrial ecosystems, *Glob. Chang. Biol.* 24 (2018) 1405–1416.  
1136 <https://doi.org/10.1111/gcb.14020>.
- 1137 [127] A. Tidjani, Comparison of formation of oxidation products during photo-oxidation of linear low  
1138 density polyethylene under different natural and accelerated weathering conditions, *Polym.*  
1139 *Degrad. Stab.* 68 (2000) 465–469. [https://doi.org/10.1016/S0141-3910\(00\)00039-2](https://doi.org/10.1016/S0141-3910(00)00039-2).

- 1140 [128] M. Hu, D. Palić, Micro- and nano-plastics activation of oxidative and inflammatory adverse  
1141 outcome pathways, *Redox Biol.* 37 (2020) 101620. <https://doi.org/10.1016/j.redox.2020.101620>.
- 1142 [129] A.-C. Greven, T. Merk, F. Karagöz, K. Mohr, M. Klapper, B. Jovanović, D. Palić, Polycarbonate  
1143 and polystyrene nanoplastic particles act as stressors to the innate immune system of fathead  
1144 minnow ( *Pimephales promelas* ), *Environ. Toxicol. Chem.* 35 (2016) 3093–3100.  
1145 <https://doi.org/10.1002/etc.3501>.
- 1146 [130] X. Shi, B. Zhou, The role of Nrf2 and MAPK pathways in PFOS-induced oxidative stress in  
1147 zebrafish embryos, *Toxicol. Sci.* 115 (2010) 391–400. <https://doi.org/10.1093/toxsci/kfq066>.
- 1148 [131] L.G.A. Barboza, L.R. Vieira, V. Branco, N. Figueiredo, F. Carvalho, C. Carvalho, L. Guilhermino,  
1149 Microplastics cause neurotoxicity, oxidative damage and energy-related changes and interact with  
1150 the bioaccumulation of mercury in the European seabass, *Dicentrarchus labrax* (Linnaeus, 1758),  
1151 *Aquat. Toxicol.* 195 (2018) 49–57. <https://doi.org/10.1016/j.aquatox.2017.12.008>.
- 1152 [132] I. Paul-Pont, C. Lacroix, C. González Fernández, H. Hégarret, C. Lambert, N. Le Goïc, L. Frère,  
1153 A.L. Cassone, R. Sussarellu, C. Fabioux, J. Guyomarch, M. Albentosa, A. Huvet, P. Soudant,  
1154 Exposure of marine mussels *Mytilus* spp. to polystyrene microplastics: Toxicity and influence on  
1155 fluoranthene bioaccumulation, *Environ. Pollut.* 216 (2016) 724–737.  
1156 <https://doi.org/10.1016/j.envpol.2016.06.039>.
- 1157 [133] F. Ribeiro, A.R. Garcia, B.P. Pereira, M. Fonseca, N.C. Mestre, T.G. Fonseca, L.M. Ilharco, M.J.  
1158 Bebianno, Microplastics effects in *Scrobicularia plana*, *Mar. Pollut. Bull.* 122 (2017) 379–391.  
1159 <https://doi.org/10.1016/j.marpolbul.2017.06.078>.
- 1160 [134] S.M.J. MohanKumar, A. Campbell, M. Block, B. Veronesi, Particulate matter, oxidative stress and  
1161 neurotoxicity, *Neurotoxicology* 29 (2008) 479–488. <https://doi.org/10.1016/j.neuro.2007.12.004>.
- 1162 [135] Q. Chen, M. Gundlach, S. Yang, J. Jiang, M. Velki, D. Yin, H. Hollert, Quantitative investigation  
1163 of the mechanisms of microplastics and nanoplastics toward zebrafish larvae locomotor activity,  
1164 *Sci. Total Environ.* 584–585 (2017) 1022–1031. <https://doi.org/10.1016/j.scitotenv.2017.01.156>.
- 1165 [136] Y. Deng, Y. Zhang, B. Lemos, H. Ren, Tissue accumulation of microplastics in mice and  
1166 biomarker responses suggest widespread health risks of exposure, *Sci. Rep.* 7 (2017) 1–10.  
1167 <https://doi.org/10.1038/srep46687>.
- 1168 [137] L. Lei, M. Liu, Y. Song, S. Lu, J. Hu, C. Cao, B. Xie, H. Shi, D. He, Polystyrene  
1169 (nano)microplastics cause size-dependent neurotoxicity, oxidative damage and other adverse  
1170 effects in *Caenorhabditis elegans*, *Environ. Sci. Nano* 5 (2018) 2009–2020.  
1171 <https://doi.org/10.1039/c8en00412a>.
- 1172 [138] A. Garcimartín, M.E. López-Oliva, M.P. González, F.J. Sánchez-Muniz, J. Benedí, Hydrogen  
1173 peroxide modifies both activity and isoforms of acetylcholinesterase in human neuroblastoma SH-  
1174 SY5Y cells, *Redox Biol.* 12 (2017) 719–726. <https://doi.org/10.1016/j.redox.2017.04.004>.
- 1175 [139] P. Michalska, R. León, When It Comes to an End: Oxidative Stress Crosstalk with Protein  
1176 Aggregation and Neuroinflammation Induce Neurodegeneration, *Antioxidants* 9 (2020) 740.  
1177 <https://doi.org/10.3390/antiox9080740>.
- 1178 [140] B. Wu, X. Wu, S. Liu, Z. Wang, L. Chen, Size-dependent effects of polystyrene microplastics on  
1179 cytotoxicity and efflux pump inhibition in human Caco-2 cells, *Chemosphere* 221 (2019) 333–  
1180 341. <https://doi.org/10.1016/j.chemosphere.2019.01.056>.

- 1181 [141] I. Brandts, M. Teles, A.P. Gonçalves, A. Barreto, L. Franco-Martinez, A. Tvarijonaviciute, M.A.  
1182 Martins, A.M.V.M. Soares, L. Tort, M. Oliveira, Effects of nanoplastics on *Mytilus*  
1183 *galloprovincialis* after individual and combined exposure with carbamazepine, *Sci. Total Environ.*  
1184 643 (2018) 775–784. <https://doi.org/10.1016/j.scitotenv.2018.06.257>.
- 1185 [142] J.-M. Zhang, J. An, Cytokines, Inflammation, and Pain, *Int. Anesthesiol. Clin.* 45 (2007) 27–37.  
1186 <https://doi.org/10.1097/AIA.0b013e318034194e>.
- 1187 [143] I. Inkielewicz-Stepniak, L. Tajber, G. Behan, H. Zhang, M.W. Radomski, C. Medina, M.J. Santos-  
1188 Martinez, The role of mucin in the toxicological impact of polystyrene nanoparticles, *Materials*  
1189 (Basel). 11 (2018) 1–12. <https://doi.org/10.3390/ma11050724>.
- 1190 [144] A.E. Lomax, K.A. Sharkey, J.B. Furness, The participation of the sympathetic innervation of the  
1191 gastrointestinal tract in disease states, *Neurogastroenterol. Motil.* 22 (2010) 7–18.  
1192 <https://doi.org/10.1111/j.1365-2982.2009.01381.x>.
- 1193 [145] M.M. Buckley, S.M. O’Mahony, D. O’Malley, Convergence of neuro-endocrine-immune  
1194 pathways in the pathophysiology of irritable bowel syndrome, *World J. Gastroenterol.* 20 (2014)  
1195 8846–8858. <https://doi.org/10.3748/wjg.v20.i27.8846>.
- 1196 [146] K.C. Cain, M.E. Jarrett, R.L. Burr, V.L. Hertig, M.M. Heitkemper, Heart rate variability is related  
1197 to pain severity and predominant bowel pattern in women with irritable bowel syndrome,  
1198 *Neurogastroenterol. Motil.* 19 (2007) 110–118. <https://doi.org/10.1111/j.1365-2982.2006.00877.x>.
- 1199 [147] C. Stasi, M. Rosselli, M. Bellini, G. Laffi, S. Milani, Altered neuro-endocrine-immune pathways  
1200 in the irritable bowel syndrome: The top-down and the bottom-up model, *J. Gastroenterol.* 47  
1201 (2012) 1177–1185. <https://doi.org/10.1007/s00535-012-0627-7>.
- 1202 [148] E.A. Mayer, K. Tillisch, S. Bradesi, Review article: Modulation of the brain-gut axis as a  
1203 therapeutic approach in gastrointestinal disease, *Aliment. Pharmacol. Ther.* 24 (2006) 919–933.  
1204 <https://doi.org/10.1111/j.1365-2036.2006.03078.x>.
- 1205 [149] C.B. Saper, The central autonomic nervous system: Conscious visceral perception and autonomic  
1206 pattern generation, *Annu. Rev. Neurosci.* 25 (2002) 433–469.  
1207 <https://doi.org/10.1146/annurev.neuro.25.032502.111311>.
- 1208 [150] S. Fukudo, Stress and visceral pain: Focusing on irritable bowel syndrome, *Pain* 154 (2013).  
1209 <https://doi.org/10.1016/j.pain.2013.09.008>.
- 1210 [151] S.E. Lee, Y. Yi, S. Moon, H. Yoon, Y.S. Park, Impact of Micro- and Nanoplastics on  
1211 Mitochondria, *Metabolites* 12 (2022). <https://doi.org/10.3390/metabo12100897>.
- 1212 [152] R. Shen, K. Yang, X. Cheng, C. Guo, X. Xing, H. Sun, D. Liu, X. Liu, D. Wang, Accumulation of  
1213 polystyrene microplastics induces liver fibrosis by activating cGAS/STING pathway, *Environ.*  
1214 *Pollut.* 300 (2022) 118986. <https://doi.org/10.1016/j.envpol.2022.118986>.
- 1215 [153] I. Florance, N. Chandrasekaran, P.M. Gopinath, A. Mukherjee, Exposure to polystyrene  
1216 nanoplastics impairs lipid metabolism in human and murine macrophages in vitro, *Ecotoxicol.*  
1217 *Environ. Saf.* 238 (2022) 113612. <https://doi.org/10.1016/j.ecoenv.2022.113612>.
- 1218 [154] L. Lu, Z. Wan, T. Luo, Z. Fu, Y. Jin, Polystyrene microplastics induce gut microbiota dysbiosis  
1219 and hepatic lipid metabolism disorder in mice, *Sci. Total Environ.* 631–632 (2018) 449–458.  
1220 <https://doi.org/10.1016/j.scitotenv.2018.03.051>.

- 1221 [155] D. He, T. Guo, J. Li, F. Wang, Optimize lettuce washing methods to reduce the risk of  
1222 microplastics ingestion: The evidence from microplastics residues on the surface of lettuce leaves  
1223 and in the lettuce washing wastewater, *Sci. Total Environ.* 868 (2023) 161726.  
1224 <https://doi.org/https://doi.org/10.1016/j.scitotenv.2023.161726>.
- 1225 [156] M.N. Moore, J. Icarus Allen, A. McVeigh, Environmental prognostics: An integrated model  
1226 supporting lysosomal stress responses as predictive biomarkers of animal health status, *Mar.*  
1227 *Environ. Res.* 61 (2006) 278–304. <https://doi.org/10.1016/j.marenvres.2005.10.005>.
- 1228 [157] S.T. Stern, P.P. Adisheshaiah, R.M. Crist, Autophagy and lysosomal dysfunction as emerging  
1229 mechanisms of nanomaterial toxicity, *Part. Fibre Toxicol.* 9 (2012). [https://doi.org/10.1186/1743-](https://doi.org/10.1186/1743-8977-9-20)  
1230 [8977-9-20](https://doi.org/10.1186/1743-8977-9-20).
- 1231 [158] I. Florance, S. Ramasubbu, A. Mukherjee, N. Chandrasekaran, Polystyrene nanoplastics  
1232 dysregulate lipid metabolism in murine macrophages in vitro, *Toxicology* 458 (2021) 152850.  
1233 <https://doi.org/10.1016/j.tox.2021.152850>.
- 1234 [159] F. Regoli, M.E. Giuliani, Oxidative pathways of chemical toxicity and oxidative stress biomarkers  
1235 in marine organisms, Elsevier Ltd, 2014. <https://doi.org/10.1016/j.marenvres.2013.07.006>.
- 1236 [160] F. Wang, M.G. Bexiga, S. Anguissola, P. Boya, J.C. Simpson, A. Salvati, K.A. Dawson, Time  
1237 resolved study of cell death mechanisms induced by amine-modified polystyrene nanoparticles,  
1238 *Nanoscale* 5 (2013) 10868–10876. <https://doi.org/10.1039/c3nr03249c>.
- 1239 [161] S. Jeon, D.K. Lee, J. Jeong, S.I. Yang, J.S. Kim, J. Kim, W.S. Cho, The reactive oxygen species as  
1240 pathogenic factors of fragmented microplastics to macrophages, *Environ. Pollut.* 281 (2021)  
1241 117006. <https://doi.org/10.1016/j.envpol.2021.117006>.
- 1242 [162] J. Windheim, L. Colombo, N.C. Battajni, L. Russo, A. Cagnotto, L. Diomede, P. Bigini, E.  
1243 Vismara, F. Fiumara, S. Gabbrielli, A. Gautieri, G. Mazzuoli-Weber, M. Salmona, L. Colnaghi,  
1244 Micro- and Nanoplastics' Effects on Protein Folding and Amyloidosis, *Int. J. Mol. Sci.* 23 (2022)  
1245 10329. <https://doi.org/10.3390/ijms231810329>.
- 1246 [163] G. Stavrou, K. Kotzampassi, Gut microbiome, surgical complications and probiotics, *Ann.*  
1247 *Gastroenterol.* 30 (2017) 45–53. <https://doi.org/10.20524/aog.2016.0086>.
- 1248 [164] P. Gazerani, Probiotics for Parkinson Disease, *Int. J. Mol. Sci.* (2019) 26. [https://www-proquest-](https://www-proquest-com.ezproxy.library.wur.nl/docview/2332370186?accountid=27871)  
1249 [com.ezproxy.library.wur.nl/docview/2332370186?accountid=27871](https://www-proquest-com.ezproxy.library.wur.nl/docview/2332370186?accountid=27871).
- 1250 [165] J.A. Bravo, M. Julio-Pieper, P. Forsythe, W. Kunze, T.G. Dinan, J. Bienenstock, J.F. Cryan,  
1251 Communication between gastrointestinal bacteria and the nervous system, *Curr. Opin. Pharmacol.*  
1252 12 (2012) 667–672. <https://doi.org/10.1016/j.coph.2012.09.010>.
- 1253 [166] A.I. Faden, D.J. Loane, Chronic Neurodegeneration After Traumatic Brain Injury: Alzheimer  
1254 Disease, Chronic Traumatic Encephalopathy, or Persistent Neuroinflammation?,  
1255 *Neurotherapeutics* 12 (2015) 143–150. <https://doi.org/10.1007/s13311-014-0319-5>.
- 1256 [167] S. Vivekanantham, S. Shah, R. Dewji, A. Dewji, C. Khatri, R. Ologunde, Neuroinflammation in  
1257 Parkinson's disease: Role in neurodegeneration and tissue repair, *Int. J. Neurosci.* 125 (2015) 717–  
1258 725. <https://doi.org/10.3109/00207454.2014.982795>.
- 1259 [168] M. Shadnoush, R.S. Hosseini, A. Khalilnezhad, L. Navai, H. Goudarzi, M. Vaezjalali, Effects of  
1260 Probiotics on Gut Microbiota in Patients with Inflammatory Bowel Disease: A Double-blind,

- 1261 Placebo-controlled Clinical Trial, *Korean J. Gastroenterol.* 65 (2015) 215–221.  
1262 <https://doi.org/10.4166/kjg.2015.65.4.215>.
- 1263 [169] X. Wang, P. Zhang, X. Zhang, Probiotics regulate gut microbiota: An effective method to improve  
1264 immunity, *Molecules* 26 (2021) 1–15. <https://doi.org/10.3390/molecules26196076>.
- 1265 [170] V. Castelli, M. D'Angelo, M. Quintiliani, E. Benedetti, M.G. Cifone, A. Cimini, The emerging  
1266 role of probiotics in neurodegenerative diseases: New hope for Parkinson's disease?, *Neural  
1267 Regen. Res.* 16 (2021) 628–634. <https://doi.org/10.4103/1673-5374.295270>.
- 1268 [171] A. Ait-Belgnaoui, H. Durand, C. Cartier, G. Chaumaz, H. Eutamene, L. Ferrier, E. Houdeau, J.  
1269 Fioramonti, L. Bueno, V. Theodorou, Prevention of gut leakiness by a probiotic treatment leads to  
1270 attenuated HPA response to an acute psychological stress in rats, *Psychoneuroendocrinology* 37  
1271 (2012) 1885–1895. <https://doi.org/10.1016/j.psyneuen.2012.03.024>.
- 1272 [172] P. He, L. Chen, L. Shao, H. Zhang, F. Lü, Municipal solid waste (MSW) landfill: A source of  
1273 microplastics? -Evidence of microplastics in landfill leachate, *Water Res.* 159 (2019) 38–45.  
1274 <https://doi.org/10.1016/j.watres.2019.04.060>.
- 1275 [173] K. Mugwanda, S. Hamese, W.F. Van Zyl, E. Prinsloo, M. Du Plessis, L.M.T. Dicks, D.B. Thimiri  
1276 Govinda Raj, Recent advances in genetic tools for engineering probiotic lactic acid bacteria.,  
1277 *Biosci. Rep.* 43 (2023). <https://doi.org/10.1042/BSR20211299>.
- 1278 [174] R.A. Börner, V. Kandasamy, A.M. Axelsen, A.T. Nielsen, E.F. Bosma, Genome editing of lactic  
1279 acid bacteria: opportunities for food, feed, pharma and biotech., *FEMS Microbiol. Lett.* 366  
1280 (2019). <https://doi.org/10.1093/femsle/fny291>.
- 1281 [175] B. del Rio, B. Redruello, M. Fernandez, M.C. Martin, V. Ladero, M.A. Alvarez, Lactic Acid  
1282 Bacteria as a Live Delivery System for the in situ Production of Nanobodies in the Human  
1283 Gastrointestinal Tract., *Front. Microbiol.* 9 (2018). <https://doi.org/10.3389/fmicb.2018.03179>.
- 1284 [176] J. Ma, Y. Lyu, X. Liu, X. Jia, F. Cui, X. Wu, S. Deng, C. Yue, Engineered probiotics, *Microb. Cell  
1285 Fact.* 21 (2022) 72. <https://doi.org/10.1186/s12934-022-01799-0>.
- 1286 [177] J. Dou, M.R. Bennett, Synthetic Biology and the Gut Microbiome., *Biotechnol. J.* 13 (2018)  
1287 e1700159. <https://doi.org/10.1002/biot.201700159>.
- 1288 [178] M.R. Charbonneau, V.M. Isabella, N. Li, C.B. Kurtz, Developing a new class of engineered live  
1289 bacterial therapeutics to treat human diseases., *Nat. Commun.* 11 (2020) 1738.  
1290 <https://doi.org/10.1038/s41467-020-15508-1>.
- 1291 [179] M. Juhas, D.R. Reuß, B. Zhu, F.M. Commichau, *Bacillus subtilis* and *Escherichia coli* essential  
1292 genes and minimal cell factories after one decade of genome engineering., *Microbiology* 160  
1293 (2014) 2341–2351. <https://doi.org/10.1099/mic.0.079376-0>.
- 1294 [180] C. Savoia, M. Volpe, G. Grassi, C. Borghi, E. Agabiti Rosei, R.M. Touyz, Personalized medicine-  
1295 a modern approach for the diagnosis and management of hypertension., *Clin. Sci. (Lond).* 131  
1296 (2017) 2671–2685. <https://doi.org/10.1042/CS20160407>.
- 1297 [181] Z.Y. Kho, S.K. Lal, The Human Gut Microbiome - A Potential Controller of Wellness and  
1298 Disease., *Front. Microbiol.* 9 (2018) 1835. <https://doi.org/10.3389/fmicb.2018.01835>.
- 1299 [182] G. Wu, X. Xiao, P. Feng, F. Xie, Z. Yu, W. Yuan, P. Liu, X. Li, Gut remediation: a potential  
1300 approach to reducing chromium accumulation using *Lactobacillus plantarum* TW1-1., *Sci. Rep.* 7

- 1301 (2017) 15000. <https://doi.org/10.1038/s41598-017-15216-9>.
- 1302 [183] N. Wang, M. Jiang, P. Zhang, H. Shu, Y. Li, Z. Guo, Y. Li, Amelioration of Cd-induced  
1303 bioaccumulation, oxidative stress and intestinal microbiota by *Bacillus cereus* in *Carassius auratus*  
1304 *gibelio.*, *Chemosphere* 245 (2020) 125613. <https://doi.org/10.1016/j.chemosphere.2019.125613>.
- 1305 [184] S.S. Giri, S. Yun, J.W. Jun, H.J. Kim, S.G. Kim, J.W. Kang, S.W. Kim, S.J. Han, V. Sukumaran,  
1306 S.C. Park, Therapeutic Effect of Intestinal Autochthonous *Lactobacillus reuteri* P16 Against  
1307 Waterborne Lead Toxicity in *Cyprinus carpio.*, *Front. Immunol.* 9 (2018) 1824.  
1308 <https://doi.org/10.3389/fimmu.2018.01824>.
- 1309 [185] H. Duan, L. Yu, F. Tian, Q. Zhai, L. Fan, W. Chen, Gut microbiota: A target for heavy metal  
1310 toxicity and a probiotic protective strategy., *Sci. Total Environ.* 742 (2020) 140429.  
1311 <https://doi.org/10.1016/j.scitotenv.2020.140429>.
- 1312 [186] V.K. Gaur, S. Gupta, P. Sharma, P. Gupta, S. Varjani, J.K. Srivastava, J.-S. Chang, X.-T. Bui,  
1313 Metabolic Cascade for Remediation of Plastic Waste: a Case Study on Microplastic Degradation,  
1314 *Curr. Pollut. Reports* 8 (2022) 30–50. <https://doi.org/10.1007/s40726-021-00210-7>.
- 1315 [187] A.K. Rana, M.K. Thakur, A.K. Saini, S.K. Mokhta, O. Moradi, T. Rydzkowski, W.F. Alsanie, Q.  
1316 Wang, S. Grammatikos, V.K. Thakur, Recent developments in microbial degradation of  
1317 polypropylene: Integrated approaches towards a sustainable environment., *Sci. Total Environ.* 826  
1318 (2022) 154056. <https://doi.org/10.1016/j.scitotenv.2022.154056>.
- 1319 [188] A.K. Wani, N. Akhtar, N. Naqash, F. Rahayu, D. Djajadi, C. Chopra, R. Singh, S.I. Mulla, F. Sher,  
1320 J.H.P. Américo-Pinheiro, Discovering untapped microbial communities through metagenomics for  
1321 microplastic remediation: recent advances, challenges, and way forward., *Environ. Sci. Pollut.*  
1322 *Res. Int.* 30 (2023) 81450–81473. <https://doi.org/10.1007/s11356-023-25192-5>.
- 1323 [189] K.L. Rogers, J.A. Carreres-Calabuig, E. Gorokhova, N.R. Posth, Micro-by-micro interactions:  
1324 How microorganisms influence the fate of marine microplastics, *Limnol. Oceanogr. Lett.* 5 (2020)  
1325 18–36. <https://doi.org/10.1002/lo2.10136>.
- 1326 [190] H. Brüßow, Probiotics and prebiotics in clinical tests: an update., *F1000Research* 8 (2019).  
1327 <https://doi.org/10.12688/f1000research.19043.1>.
- 1328 [191] G. Athalye-Jape, S. Rao, S. Patole, *Lactobacillus reuteri* DSM 17938 as a Probiotic for Preterm  
1329 Neonates: A Strain-Specific Systematic Review., *JPEN. J. Parenter. Enteral Nutr.* 40 (2016) 783–  
1330 794. <https://doi.org/10.1177/0148607115588113>.
- 1331 [192] M. Mennini, L. Dahdah, M.C. Artesani, A. Fiocchi, A. Martelli, Probiotics in Asthma and Allergy  
1332 Prevention., *Front. Pediatr.* 5 (2017) 165. <https://doi.org/10.3389/fped.2017.00165>.
- 1333 [193] R. Dudek-Wicher, A. Junka, J. Paleczny, M. Bartoszewicz, Clinical Trials of Probiotic Strains in  
1334 Selected Disease Entities., *Int. J. Microbiol.* 2020 (2020) 8854119.  
1335 <https://doi.org/10.1155/2020/8854119>.
- 1336 [194] K.-C. Hsiao, A.-L. Ponsonby, C. Axelrad, S. Pitkin, M.L.K. Tang, Long-term clinical and  
1337 immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-  
1338 year follow-up of a randomised, double-blind, placebo-controlled trial., *Lancet. Child Adolesc.*  
1339 *Heal.* 1 (2017) 97–105. [https://doi.org/10.1016/S2352-4642\(17\)30041-X](https://doi.org/10.1016/S2352-4642(17)30041-X).
- 1340 [195] C. Gonzalez-Gonzalez, T. Gibson, P. Jauregi, Novel probiotic-fermented milk with angiotensin I-

- 1341 converting enzyme inhibitory peptides produced by *Bifidobacterium bifidum* MF 20/5., *Int. J.*  
1342 *Food Microbiol.* 167 (2013) 131–137. <https://doi.org/10.1016/j.ijfoodmicro.2013.09.002>.
- 1343 [196] Y. Endo, N. Kimura, I. Ikeda, K. Fujimoto, H. Kimoto, Adsorption of bisphenol A by lactic acid  
1344 bacteria, *Lactococcus*, strains, *Appl. Microbiol. Biotechnol.* 74 (2007) 202–207.  
1345 <https://doi.org/10.1007/s00253-006-0632-y>.
- 1346 [197] M. Mergler, K. Wolf, M. Zimmermann, Development of a bisphenol A-adsorbing yeast by surface  
1347 display of the *Kluyveromyces fragilis* yellow enzyme on *Pichia pastoris*, *Appl. Microbiol. Biotechnol.* 63  
1348 (2004) 418–421. <https://doi.org/10.1007/s00253-003-1361-0>.
- 1349 [198] N. Garcia-Gonzalez, R. Prete, M. Perugini, C. Merola, N. Battista, A. Corsetti, Probiotic  
1350 antigenotoxic activity as a DNA bioprotective tool: A minireview with focus on endocrine  
1351 disruptors, *FEMS Microbiol. Lett.* 367 (2020). <https://doi.org/10.1093/femsle/fnaa041>.
- 1352 [199] S. Solouki, M.R. Fazeli, S. Solouki, Efficiency of multispecies probiotic supplements in  
1353 Bioremoval of bisphenol A: An in vitro study, *Appl. Food Biotechnol.* 5 (2018) 37–45.  
1354 <https://doi.org/10.22037/afb.v5i1.18191>.
- 1355 [200] J. Li, C.Y.J. Sung, N. Lee, Y. Ni, J. Pihlajamäki, G. Panagiotou, H. El-Nezami, Probiotics  
1356 modulated gut microbiota suppresses hepatocellular carcinoma growth in mice, *Proc. Natl. Acad.*  
1357 *Sci. U. S. A.* 113 (2016) E1306–E1315. <https://doi.org/10.1073/pnas.1518189113>.
- 1358 [201] M. Trinder, J.E. Bisanz, J.P. Burton, G. Reid, Probiotic lactobacilli: A potential prophylactic  
1359 treatment for reducing pesticide absorption in humans and wildlife, *Benef. Microbes* 6 (2015)  
1360 841–847. <https://doi.org/10.3920/BM2015.0022>.
- 1361 [202] Y. ting Zhu, C. xiang Yang, B. Bin Luo, K. Zhou, S. liang Liu, Efficiency of dairy strains of lactic  
1362 acid bacteria to bind bisphenol A in phosphate buffer saline, *Food Control* 73 (2017) 1203–1209.  
1363 <https://doi.org/10.1016/j.foodcont.2016.10.039>.
- 1364 [203] M.G. Zlatnik, Endocrine-Disrupting Chemicals and Reproductive Health, *J. Midwifery Women's*  
1365 *Heal.* 61 (2016) 442–455. <https://doi.org/10.1111/jmwh.12500>.
- 1366 [204] A. Monteagudo-Mera, R.A. Rastall, G.R. Gibson, D. Charalampopoulos, A. Chatzifragkou,  
1367 Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human  
1368 health, *Appl. Microbiol. Biotechnol.* 103 (2019) 6463–6472. <https://doi.org/10.1007/s00253-019-09978-7>.
- 1370 [205] D.R. Snyderman, The Safety of Probiotics, *Clin. Infect. Dis.* 46 (2008) S104–S111.  
1371 <https://doi.org/10.1086/523331>.
- 1372 [206] Y. Zhang, P. Zhang, Y. Li, Gut microbiota-mediated ferroptosis contributes to mercury exposure-  
1373 induced brain injury in common carp, *Metallomics* 14 (2022).  
1374 <https://doi.org/10.1093/mtomcs/mfab072>.
- 1375 [207] M. van den Nieuwboer, R.J. Brummer, F. Guarner, L. Morelli, M. Cabana, E. Claassen, Safety of  
1376 probiotics and synbiotics in children under 18 years of age, *Benef. Microbes* 6 (2015) 615–630.  
1377 <https://doi.org/10.3920/BM2014.0157>.
- 1378 [208] S. Meini, R. Laureano, L. Fani, C. Tascini, A. Galano, A. Antonelli, G.M. Rossolini, Breakthrough  
1379 *Lactobacillus rhamnosus* GG bacteremia associated with probiotic use in an adult patient with  
1380 severe active ulcerative colitis: case report and review of the literature, *Infection* 43 (2015) 777–



- 1381 781. <https://doi.org/10.1007/s15010-015-0798-2>.
- 1382 [209] S. Hempel, S. Newberry, A. Ruelaz, Z. Wang, J.N. V Miles, M.J. Suttorp, B. Johnsen, R.  
1383 Shanman, W. Slusser, N. Fu, A. Smith, B. Roth, J. Polak, A. Motala, T. Perry, P.G. Shekelle,  
1384 Safety of probiotics used to reduce risk and prevent or treat disease., *Evid. Rep. Technol. Assess.*  
1385 (Full. Rep). (2011) 1–645. <http://www.ncbi.nlm.nih.gov/pubmed/23126627>.
- 1386 [210] M.P. Dore, S. Bibbò, G. Fresi, G. Bassotti, G.M. Pes, Side Effects Associated with Probiotic Use  
1387 in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of  
1388 Randomized Controlled Trials, *Nutrients* 11 (2019) 2913. <https://doi.org/10.3390/nu11122913>.
- 1389 [211] Y. Derwa, D.J. Gracie, P.J. Hamlin, A.C. Ford, Systematic review with meta-analysis: the efficacy  
1390 of probiotics in inflammatory bowel disease, *Aliment. Pharmacol. Ther.* 46 (2017) 389–400.  
1391 <https://doi.org/10.1111/apt.14203>.
- 1392 [212] A.C. Ford, L.A. Harris, B.E. Lacy, E.M.M. Quigley, P. Moayyedi, Systematic review with  
1393 meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel  
1394 syndrome, *Aliment. Pharmacol. Ther.* 48 (2018) 1044–1060. <https://doi.org/10.1111/apt.15001>.
- 1395 [213] N.T. Williams, Probiotics, *Am. J. Heal. Pharm.* 67 (2010) 449–458.  
1396 <https://doi.org/10.2146/ajhp090168>.
- 1397 [214] K.D. Karpa, Probiotics for *Clostridium difficile* Diarrhea: Putting It into Perspective, *Ann.*  
1398 *Pharmacother.* 41 (2007) 1284–1287. <https://doi.org/10.1345/aph.1K228>.
- 1399 [215] E. Pessione, S. Cirrincione, Bioactive Molecules Released in Food by Lactic Acid Bacteria:  
1400 Encrypted Peptides and Biogenic Amines., *Front. Microbiol.* 7 (2016) 876.  
1401 <https://doi.org/10.3389/fmicb.2016.00876>.
- 1402 [216] W.E. Bennett, Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome  
1403 and Inflammatory Bowel Disease., *Drug Saf.* 39 (2016) 295–305. [https://doi.org/10.1007/s40264-](https://doi.org/10.1007/s40264-015-0349-x)  
1404 [015-0349-x](https://doi.org/10.1007/s40264-015-0349-x).
- 1405 [217] F.S. Tom, K.J. Tucker, C.M. McCracken, J.C. McGregor, S.J. Gore, Infectious complications of  
1406 probiotic use: A matched case–control study, *Infect. Control Hosp. Epidemiol.* 43 (2022) 1498–  
1407 1500. <https://doi.org/10.1017/ice.2021.261>.
- 1408 [218] Z. Liu, W. Liu, C. Ran, J. Hu, Z. Zhou, Abrupt suspension of probiotics administration may  
1409 increase host pathogen susceptibility by inducing gut dysbiosis, *Sci. Rep.* 6 (2016) 23214.  
1410 <https://doi.org/10.1038/srep23214>.
- 1411 [219] G.S. Claudiano, F.R. de Moraes, D.C. Fernandes, J.S. Vantini, J. Yunis-Aguinaga, S.F. Eto, F.A.  
1412 Marinho-Neto, H.J.A. Macedo, W.G. Manrique, J.R.E. Moraes, Experimental infection by  
1413 *Aeromonas hydrophila* in *Piaractus mesopotamicus*: DL50, neurological disturbances, and  
1414 mortality, *Comp. Clin. Path.* 29 (2020) 1119–1126. <https://doi.org/10.1007/s00580-020-03159-z>.
- 1415 [220] N. Madangarli, F. Bonsack, R. Dasari, S. Sukumari–Ramesh, Intracerebral Hemorrhage: Blood  
1416 Components and Neurotoxicity, *Brain Sci.* 9 (2019) 316. <https://doi.org/10.3390/brainsci9110316>.
- 1417 [221] W.S. Dodd, E.J. Panther, K. Pierre, J.S. Hernandez, D. Patel, B. Lucke-Wold, Traumatic Brain  
1418 Injury and Secondary Neurodegenerative Disease, *Trauma Care* 2 (2022) 510–522.  
1419 <https://doi.org/10.3390/traumacare2040042>.
- 1420 [222] J. Ding, S. Zhang, R.M. Razanajatovo, H. Zou, W. Zhu, Accumulation, tissue distribution, and

- 1421 biochemical effects of polystyrene microplastics in the freshwater fish red tilapia (*Oreochromis*  
1422 *niloticus*), *Environ. Pollut.* 238 (2018) 1–9. <https://doi.org/10.1016/j.envpol.2018.03.001>.
- 1423 [223] Q. Chen, D. Yin, Y. Jia, S. Schiwiy, J. Legradi, S. Yang, H. Hollert, Enhanced uptake of BPA in  
1424 the presence of nanoplastics can lead to neurotoxic effects in adult zebrafish, *Sci. Total Environ.*  
1425 609 (2017) 1312–1321. <https://doi.org/10.1016/j.scitotenv.2017.07.144>.
- 1426 [224] W. Zhang, Z. Liu, S. Tang, D. Li, Q. Jiang, T. Zhang, Transcriptional response provides insights  
1427 into the effect of chronic polystyrene nanoplastic exposure on *Daphnia pulex*, *Chemosphere* 238  
1428 (2020) 124563. <https://doi.org/10.1016/j.chemosphere.2019.124563>.
- 1429 [225] Y.-L. Wang, Y.-H. Lee, I.-J. Chiu, Y.-F. Lin, H.-W. Chiu, Potent Impact of Plastic Nanomaterials  
1430 and Micromaterials on the Food Chain and Human Health, *Int. J. Mol. Sci.* 21 (2020) 1727.  
1431 <https://doi.org/10.3390/ijms21051727>.
- 1432 [226] Y. Chae, D. Kim, S.W. Kim, Y.-J. An, Trophic transfer and individual impact of nano-sized  
1433 polystyrene in a four-species freshwater food chain., *Sci. Rep.* 8 (2018) 284.  
1434 <https://doi.org/10.1038/s41598-017-18849-y>.
- 1435 [227] A.-C. Greven, T. Merk, F. Karagöz, K. Mohr, M. Klapper, B. Jovanović, D. Palić, Polycarbonate  
1436 and polystyrene nanoplastic particles act as stressors to the innate immune system of fathead  
1437 minnow (*Pimephales promelas*), *Environ. Toxicol. Chem.* 35 (2016) 3093–3100.  
1438 <https://doi.org/10.1002/etc.3501>.
- 1439 [228] W. Lv, Y. Shen, S. Xu, B. Wu, Z. Zhang, S. Liu, Underestimated health risks: Dietary restriction  
1440 magnify the intestinal barrier dysfunction and liver injury in mice induced by polystyrene  
1441 microplastics, *Sci. Total Environ.* 898 (2023) 165502.  
1442 <https://doi.org/10.1016/j.scitotenv.2023.165502>.
- 1443 [229] M. Gómez de Cedrón, A. Ramírez de Molina, Precision nutrition to target lipid metabolism  
1444 alterations in cancer, in: *Precis. Med. Investig. Pract. Provid.*, Elsevier, 2020: pp. 291–299.  
1445 <https://doi.org/10.1016/B978-0-12-819178-1.00028-9>.
- 1446 [230] A.H. Tan, J.W. Hor, C.W. Chong, S.-Y. Lim, Probiotics for Parkinson’s disease: Current evidence  
1447 and future directions., *JGH Open an Open Access J. Gastroenterol. Hepatol.* 5 (2021) 414–419.  
1448 <https://doi.org/10.1002/jgh3.12450>.
- 1449 [231] K.R. Gandhi, A. Saadabadi, Levodopa (L-Dopa), 2024.  
1450 <http://www.ncbi.nlm.nih.gov/pubmed/30869416>.
- 1451 [232] J. Jankovic, Complications and limitations of drug therapy for Parkinson’s disease., *Neurology* 55  
1452 (2000) S2-6. <http://www.ncbi.nlm.nih.gov/pubmed/11188970>.
- 1453 [233] J. Jankovic, E.K. Tan, Parkinson’s disease: etiopathogenesis and treatment, *J. Neurol. Neurosurg.*  
1454 *& Psychiatry* 91 (2020) 795 LP – 808. <https://doi.org/10.1136/jnnp-2019-322338>.
- 1455 [234] H. Sun, F. Zhao, Y. Liu, T. Ma, H. Jin, K. Quan, B. Leng, J. Zhao, X. Yuan, Z. Li, F. Li, L.-Y.  
1456 Kwok, S. Zhang, Z. Sun, J. Zhang, H. Zhang, Probiotics synergized with conventional regimen in  
1457 managing Parkinson’s disease, *Npj Park. Dis.* 8 (2022) 62. <https://doi.org/10.1038/s41531-022-00327-6>.
- 1459 [235] F.J. Clissold, B.J. Tedder, A.D. Conigrave, S.J. Simpson, The gastrointestinal tract as a nutrient-  
1460 balancing organ, *Proc. R. Soc. B Biol. Sci.* 277 (2010) 1751–1759.

- 1461 <https://doi.org/10.1098/rspb.2009.2045>.
- 1462 [236] W.C. LI, H.F. TSE, L. FOK, Plastic waste in the marine environment: A review of sources,  
1463 occurrence and effects, *Sci. Total Environ.* 566–567 (2016) 333–349.  
1464 <https://doi.org/10.1016/j.scitotenv.2016.05.084>.
- 1465 [237] I. Pan, P.K. Issac, M.M. Rahman, A. Guru, J. Arockiaraj, Gut-Brain Axis a Key Player to Control  
1466 Gut Dysbiosis in Neurological Diseases, *Mol. Neurobiol.* (2023). [https://doi.org/10.1007/s12035-](https://doi.org/10.1007/s12035-023-03691-3)  
1467 [023-03691-3](https://doi.org/10.1007/s12035-023-03691-3).
- 1468 [238] V. Danilenko, A. Devyatkin, M. Marsova, M. Shibilova, R. Ilyasov, V. Shmyrev, Common  
1469 Inflammatory Mechanisms in COVID-19 and Parkinson’s Diseases: The Role of Microbiome,  
1470 Pharmabiotics and Postbiotics in Their Prevention, *J. Inflamm. Res.* Volume 14 (2021) 6349–  
1471 6381. <https://doi.org/10.2147/JIR.S333887>.
- 1472 [239] M. Hu, D. Palić, Micro- and nano-plastics activation of oxidative and inflammatory adverse  
1473 outcome pathways, *Redox Biol.* 37 (2020) 101620. <https://doi.org/10.1016/j.redox.2020.101620>.
- 1474 [240] R. Dong, C. Zhou, S. Wang, Y. Yan, Q. Jiang, Probiotics ameliorate polyethylene microplastics-  
1475 induced liver injury by inhibition of oxidative stress in Nile tilapia (*Oreochromis niloticus*), *Fish*  
1476 *Shellfish Immunol.* 130 (2022) 261–272. <https://doi.org/10.1016/j.fsi.2022.09.022>.
- 1477 [241] A. Hayati, M. Pramudya, H. Soepriandono, A.R. Astri, M.R. Kusuma, S. Maulidah, W.  
1478 Adriansyah, F.R.P. Dewi, Assessing the recovery of steroid levels and gonadal histopathology of  
1479 tilapia exposed to polystyrene particle pollution by supplementary feed., *Vet. World* 15 (2022)  
1480 517–523. <https://doi.org/10.14202/vetworld.2022.517-523>.
- 1481 [242] J. Bazeli, Z. Banikazemi, M.R. Hamblin, R. Sharafati Chaleshtori, Could probiotics protect against  
1482 human toxicity caused by polystyrene nanoplastics and microplastics?, *Front. Nutr.* 10 (2023)  
1483 1186724. <https://doi.org/10.3389/fnut.2023.1186724>.
- 1484 [243] M. Ahmadmoradi, M. Alishahi, S. Soltanian, A. Shahriari, A. Yektaseresht, Effects of  
1485 encapsulation of *Lactobacillus plantarum* on probiotic potential and reducing lead toxicity in  
1486 rainbow trout (*Oncorhynchus mykiss* Walbaum), *Aquac. Int.* (2023).  
1487 <https://doi.org/10.1007/s10499-023-01164-x>.
- 1488 [244] H. Liao, S. Liu, M. Junaid, D. Gao, W. Ai, G. Chen, J. Wang, Di-(2-ethylhexyl) phthalate  
1489 exacerbated the toxicity of polystyrene nanoplastics through histological damage and intestinal  
1490 microbiota dysbiosis in freshwater *Micropterus salmoides*., *Water Res.* 219 (2022) 118608.  
1491 <https://doi.org/10.1016/j.watres.2022.118608>.
- 1492 [245] Y. Zhang, B. Hou, T. Liu, Y. Wu, Z. Wang, Probiotics improve polystyrene microplastics-induced  
1493 male reproductive toxicity in mice by alleviating inflammatory response, *Ecotoxicol. Environ. Saf.*  
1494 263 (2023) 115248. <https://doi.org/https://doi.org/10.1016/j.ecoenv.2023.115248>.
- 1495 [246] H. Yu, B. Wu, X.-X. Zhang, S. Liu, J. Yu, S. Cheng, H.-Q. Ren, L. Ye, Arsenic Metabolism and  
1496 Toxicity Influenced by Ferric Iron in Simulated Gastrointestinal Tract and the Roles of Gut  
1497 Microbiota., *Environ. Sci. Technol.* 50 (2016) 7189–7197.  
1498 <https://doi.org/10.1021/acs.est.6b01533>.
- 1499 [247] C.C. Gilmour, M. Podar, A.L. Bullock, A.M. Graham, S.D. Brown, A.C. Somenahally, A. Johs,  
1500 R.A.J. Hurt, K.L. Bailey, D.A. Elias, Mercury methylation by novel microorganisms from new  
1501 environments., *Environ. Sci. Technol.* 47 (2013) 11810–11820. <https://doi.org/10.1021/es403075t>.

- 1502 [248] K.Y. Hur, M.-S. Lee, Gut Microbiota and Metabolic Disorders., *Diabetes Metab. J.* 39 (2015)  
 1503 198–203. <https://doi.org/10.4093/dmj.2015.39.3.198>.
- 1504 [249] J. Plaza-Diaz, F.J. Ruiz-Ojeda, M. Gil-Campos, A. Gil, Mechanisms of Action of Probiotics., *Adv.*  
 1505 *Nutr.* 10 (2019) S49–S66. <https://doi.org/10.1093/advances/nmy063>.
- 1506 [250] C. O’Mahony, P. Scully, D. O’Mahony, S. Murphy, F. O’Brien, A. Lyons, G. Sherlock, J.  
 1507 MacSharry, B. Kiely, F. Shanahan, L. O’Mahony, Commensal-induced regulatory T cells mediate  
 1508 protection against pathogen-stimulated NF-kappaB activation., *PLoS Pathog.* 4 (2008) e1000112.  
 1509 <https://doi.org/10.1371/journal.ppat.1000112>.
- 1510 [251] P. Hemarajata, J. Versalovic, Effects of probiotics on gut microbiota: mechanisms of intestinal  
 1511 immunomodulation and neuromodulation., *Therap. Adv. Gastroenterol.* 6 (2013) 39–51.  
 1512 <https://doi.org/10.1177/1756283X12459294>.
- 1513 [252] Z. Wan, C. Wang, J. Zhou, M. Shen, X. Wang, Z. Fu, Y. Jin, Effects of polystyrene microplastics  
 1514 on the composition of the microbiome and metabolism in larval zebrafish, *Chemosphere* 217  
 1515 (2019) 646–658. <https://doi.org/https://doi.org/10.1016/j.chemosphere.2018.11.070>.

1516

1517 **FIGURE LEGEND**

1518 **Fig.1.Schematic Representation of Microplastics (MP) Generation and Their Portals of Entry to Establish**  
 1519 **Severe Health Issues in Human**

1520 **Fig.2.Schematic Representation of Gut–Brain Axis.**

1521 **Fig.3. Schematic Representation of MP Induced Dysbiosis. Gut Brain Axis which controls the entire**  
 1522 **homeostasis of the body upon alteration disrupt the normal functions resulting in Chronic Disorders.**

1523 **Fig.4.Schematic representation of MP induced biochemical pathways which disrupt the homeostasis and**  
 1524 **reestablishment of it with probiotics. A: Blocking of NFκβ pathway by Probiotics; B: SCFA mediated anti**  
 1525 **inflammation; C: Blocking of Nox dependent pathway by Probiotics; D: Controlling ROS by CAT, SOD, GPx**  
 1526 **and reduced DNA Damage**

1527 **Fig.5.Disruption of Homeostasis. A. Normal condition in which Gut Brain Axis regulates physiological,**  
 1528 **biochemical and neuronal pathways, B. MP induced PD brain in which altered Gut Brain Axis triggers**  
 1529 **several altered mechanisms to hinder physiological, biochemical and neuronal pathways**

1530 **Fig.6.Probiotics the New Therapeutic Approach to Control Gut Dysbiosis Induced by MPs**

1531 **TABLELEGEND**

1532 **Table 1: VARIOUS PROBIOTICS AND THEIR PROBABLE MODE OF ACTIONS TO NEUTRALIZE MP**  
 1533 **TOXICITIES**

1534 **Table 2: MP INDUCED GUT MICROBIAL COMPOSITION VARIATION IN DIFFERENT SPECIES OF**  
 1535 **ANIMALS**

1536 **Table 3: EFFECT OF MP ON VARIOUS MAMMALIAN GLANDS**

1537

1538 **Table 1**  
 1539 **VARIOUS PROBIOTICS AND THEIR PROBABLE MODE OF ACTIONS TO NEUTRALIZE**  
 1540 **MP TOXICITIES**  
 1541

SL. NO	PROBIOTICS	MODEL	MPS	PROBLEMS	MODE OF ACTION	REFERENCES
1	AquaStar® (commercial probiotics)	Nile tilapia ( <i>Oreochromis niloticus</i> )	Polystyrene (PS)-MPs	a) Hepatic oxidative stress b) Activation of Mitogen-Activated Protein Kinase (MAPK) signaling c) Autophagy d) Inhibition of ERK signaling e) Activation of p38MAPK components	Nuclear factor erythroid 2-related factor 2 (Nrf2) down regulate p38MAPK	[240]
2	Commercial-probiotic pellets [200 mL/kg, $1 \times 10^8$ colony-forming unit (CFU)/mL]	Tilapia	Polystyrene (PS)-MPs	a) Altered levels of estradiol b) Testosterone	(Nrf2) down regulate p38MAPK attenuation of nuclear transcription factor $\kappa$ B (NF- $\kappa$ B) preventing apoptosis	[241,242]
3	<i>Lactobacillus plantarum</i> encapsulated with alginate/chitosan NP	<i>Oncorhynchus mykiss</i>	MP coated with Pb	a) Lead toxicity mitigation, growth, b) hematological development c) modification in the intestinal enzyme activity	Bile salt hydrolase mediated deconjugation of bile acids lowering the activity of $\beta$ -glucuronidase to suppress the intestinal damage	[243]

4	<i>Bacteroidetes</i> and <i>Proteobacteria</i>	<i>Micropterus salmoides</i>	PS-NPs single and DEHP-PSNP combined exposures on	a) The growth b) ROS c) Histopathology d) Intestinal microbiota composition	compete for receptors and binding sites with pathogen and restore intestinal barrier	[244]
<b>SL. NO</b>	<b>PROBIOTICS</b>	<b>MODEL</b>	<b>MPS</b>	<b>PROBLEMS</b>	<b>MODE OF ACTION</b>	<b>REFERENCES</b>
5	<i>Lactobacillus</i> , <i>Bifidobacterium longum</i> , and <i>Enterococcus</i>  Combined formulation for FMT	Mice	Polystyrene microplastics (PS- MP)	Male reproductive toxicity	Anti-inflammatory  Cytokine production  TLR2/TLR4/MyD88 Signalling	[242,245]
6	<i>Bacillus</i>	Mice	MP surface coated with HM (Pb, Cd, Hg, As, Al, Cu, Mn, Cr)	Heavy metal toxicities	Insoluble metal complex by siderophores  Insoluble metal precipitation	[246]
7	<i>Lactobacillus sp</i>	Mice, Rat	MP surface coated with HM  Pb, Cd, Mn  Pb, Cd, Al, Cu	Heavy metal toxicities	Reduce its availability and release it through feces  a) By trapping through transporter protein  b) By EPS binding protein	[113,247]
8	<i>Bacteriodes</i>	Zebrafish	MP surface coated with HM Hg As, Bi	Heavy metal toxicities	Reduction of metal toxicities by metal  a) Methylation b) Demethylation c) Thiolation d) Reduction e) Oxidation	[100,185,247]

9	<i>L. rhamnosus</i> ATCC 7469	Zebrafish  Caco-2 cell line	PE-MPs and PS-MPs  MP coated with <i>E. coli</i> strain (serotype O149: K91, K88ac)	a) Altered barrier b) Altered gut colonization c) Inflammation	a) Upregulation of mRNA level for the Muc1, Muc2, Muc3, Klf4, Mepln- $\beta$ , and Retnlb genes  b) Toll-like receptor (TLR)-4 and nucleotide binding oligomerization domain-containing protein (NOD) 2 (NOD2) mediated enhanced Akt phosphorylation and expression of tight junction protein	[100,242]
<b>SL. NO</b>	<b>PROBIOTICS</b>	<b>MODEL</b>	<b>MPS</b>	<b>PROBLEMS</b>	<b>MODE OF ACTION</b>	<b>REFERENCES</b>
10	<i>L. acidophilus</i> R0011 <i>L. rhamnosus</i> R0052	<i>P. nana</i> and Mitten Crab <i>E. sinensis</i>	PE MP	MP-induced ROS and activate ERK and p38 MAPR	Nrf2 down regulate p38MAPK	[124]
11	<i>L. plantarum</i> 299v  <i>Bifidobacteriasp</i>	Human and Mice	MP carrying pathogen	<i>C. difficile</i> -associated diarrhea  <i>E. coli</i> O157:H7 infection	SCFA G protein-coupled receptor (GPR) 41 and GPR43  ATP-binding-cassette-type carbohydrate transporter mediated protection like decreased lipolysis and inflammation and increased adipogenesis and leptin release	[248,249]

SL. NO	PROBIOTICS	MODEL	MPS	PROBLEMS	MODE OF ACTION	REFERENCES
12	<i>B. breve</i> C50  <i>B. longum</i> subsp. <i>infantis</i> 35624	Mice	PE/PS with <i>Salmonella</i>	Intestinal Homeostasis  Inflammation	CXCL8 secretion by epithelial cells via AP1 transcription factor subunit and I $\kappa$ B- $\alpha$ a decreased phosphorylation of p38-MAPK and I $\kappa$ B- $\alpha$ molecules  attenuation of nuclear transcription factor $\kappa$ B (NF- $\kappa$ B)  compete for receptors and binding sites with pathogen and restore intestinal barrier	[250,251]



1543 Table 2

1544 MP INDUCED GUT MICROBIAL COMPOSITION VARIATION IN DIFFERENT SPECIES OF  
1545 ANIMALS

MP	Species affected	Decreasing Phylum/ Genus	Increasing Phylum / Genus	Functional changes	Reference
PE	Zebrafish	<i>Firmicutes, Bacteroides, Actinobacteria, β-Proteobacteria, γ-Proteobacteria, Acidobacteria, Gemmatimonadetes and Cyanobacteria /Pseudomonas, Ralstonia, Stenotrophomonas, Chryseobacterium, Rhizobiaceae, Sphingomonas, Variovorax, Rhodococcus, Roseburia, Butyrivibrio, Lysobacter, Phascolarctobacterium, Mycobacterium, Micromonospora and Gaiella</i>	Proteobacteria, Chloroflexi and Fusobacteria /Aeromonas, Shewanella, Microbacterium, Nevskia and Methyloversatilis	The levels of <ul style="list-style-type: none"> <li>✓ Triglyceride (TG),</li> <li>✓ Total cholesterol (TCHO),</li> <li>✓ Non-esterified fatty acid (NEFA),</li> <li>✓ Total bile acid (TBA),</li> <li>✓ Glucose (GLU)</li> <li>✓ Pyruvic acid</li> </ul> Transcription of genes: <ul style="list-style-type: none"> <li>✓ Glycolipid</li> <li>✓ Metabolism-related</li> <li>✓ Genes and phospholipid metabolism-related genes</li> </ul> Metabolites: <ul style="list-style-type: none"> <li>✓ Phospholipids</li> </ul>	[19]  [100]
PS		<i>Bacteroidetes, γ-Proteobacteria /Sphaerotilus, Haliangium, Leptothrix, Pseudomonas, Methylobacterium</i>	Firmicutes /Methyloversatilis, Polynucleobacter, Legionella, Ottowia, Flectobacillus and Methylophilus	Metabolites: <ul style="list-style-type: none"> <li>✓ Carbohydrates,</li> <li>✓ Fatty acids,</li> <li>✓ Amino acids,</li> <li>✓ Nucleic acid</li> </ul> Transcription of genes: <ul style="list-style-type: none"> <li>✓ Glucose metabolism</li> <li>✓ Glycolysis-related</li> <li>✓ Lipid metabolism</li> </ul>	[252]
PP		<i>Actinobacteria / Aeromonas and Pseudomonas</i>	Proteobacteria / Gordonina	Enriched GO biological processes: <ul style="list-style-type: none"> <li>✓ Lipid metabolism,</li> <li>✓ Hormone metabolism</li> <li>✓ Protein secretion</li> </ul>	
PS	Large yellow croaker	<i>Proteobacteria / Ruegeria, Vibrio and Microscilla</i>	Bacteroidetes, Firmicutes /Alloprevotella, Parabacteroides, Bifidobacterium, Alistipes, Bacteroides, Aliivibrio, Lactobacillus and Weissella	Bacterial gene functional prediction: <ul style="list-style-type: none"> <li>✓ Metabolism,</li> <li>✓ Organismal systems,</li> <li>✓ Biosynthesis of other secondary metabolites and circulatory system</li> </ul>	[41]

PVC	Sea bass	No changes	no changes	<p>Extracellular enzymatic activities decreased:</p> <ul style="list-style-type: none"> <li>✓ Leucine</li> <li>✓ Aminopeptidase,</li> <li>✓ Beta- glucosidase</li> <li>✓ Alkaline phosphatase</li> </ul> <p>Carbon source utilization:</p> <ul style="list-style-type: none"> <li>✓ Complex carbon sources,</li> <li>✓ Amino acids,</li> <li>✓ Carbohydrates,</li> <li>✓ Carboxylic acids</li> </ul>	[72]  [73]
<b>MP</b>	<b>Species affected</b>	<b>Decreasing Phylum/ Genus</b>	<b>Increasing Phylum / Genus</b>	<b>Functional changes</b>	<b>Reference</b>
PS <5µm		no change	Fusobacteria, Proteobacteria, Cyanobacteria and Chloroflexi / Pseudomonas and Rhodococcus	not specific	[19]
PS 5µm and above	Crab	<i>Firmicutes, Bacteroidetes and Nitrospirae / Dysgonomonas and Acinetobacter</i>	Cyanobacteria and Chloroflexi / Pseudomonas and Rhodococcus	not specific	[128]

1547 **Table 3**1548 **EFFECT OF MP ON VARIOUS MAMMALIAN GLANDS**

Gland/ System involved	Endocrine Disrupter	Species	Consequences	References
Thyroid Gland	MP	Human	<ul style="list-style-type: none"> <li>Thyroid dysfunction</li> <li>Metabolic and developmental abnormalities</li> </ul>	[64] [113] [115]
	PS MP	Rat	<ul style="list-style-type: none"> <li>T3 and circulating THs levels were decreased and TSH significantly increased.</li> <li>Ectopic thymus Ultimobranchial cyst formation</li> <li>Increased level of T3, FT3/FT4 ratio, and decreased level of TSH</li> </ul>	
	MP+ Phthalates	Human	<ul style="list-style-type: none"> <li>Thyroid epithelial cell hypertrophy and hyperplasia</li> <li>Thyroid hyperactivity,</li> <li>Disruption of the hypothalamic-pituitary-thyroid [HPT] axis,</li> <li>Thyroid antagonistic interaction,</li> <li>Altered FT3 and FT4</li> </ul>	
	MP+ Bisphenol A [BPA]	Rats	<ul style="list-style-type: none"> <li>Inhibits T3 receptor binding ability,</li> <li>Thyroid antagonist,</li> <li>Thyroid oxidative damage</li> </ul>	
	MP+ Polybrominated diphenyl ethers [PBDEs]	Rats and Human	<ul style="list-style-type: none"> <li>Serum T4 reduction,</li> <li>hypothyroidism, altered T4 levels in umbilical-cord blood,</li> <li>altered T3 and T4 levels</li> </ul>	
	MP+ Polychlorinated Biphenyls (PCBs)	Rat	<ul style="list-style-type: none"> <li>Reduced TT4</li> <li>Reduced FT4 levels</li> </ul>	
	MP+ Mercury	Human	<ul style="list-style-type: none"> <li>Thyroid cancer,</li> <li>Hypothyroidism,</li> <li>Autoimmune thyroiditis</li> </ul>	
Male Reproductive System	MP	Mice	<ul style="list-style-type: none"> <li>Reduced sperm quality,</li> <li>abnormal testicular spermatogenesis</li> </ul>	[87] [115]
	MP	Swine	<ul style="list-style-type: none"> <li>Increased apoptosis and necrosis in testes,</li> <li>decreased viability of testicular cells</li> </ul>	
	PS-MPs	Mice	<ul style="list-style-type: none"> <li>Oxidative stress in testes</li> <li>reduced sperm motility</li> </ul>	
	MP+ Phthalates	Rats and Mice	<ul style="list-style-type: none"> <li>Oxidative stress in testes,</li> <li>altered sperm's physiology,</li> <li>anti-androgenic effects</li> </ul>	

	<b>MP+ TBT</b>	Syrian hamsters	<ul style="list-style-type: none"> <li>• Adverse steroidogenic enzymes activity,</li> <li>• impaired testosterone production,</li> <li>• defective spermatozoa</li> </ul>	
	<b>MP+ Chromium, lead and Mercury</b>	Mice, Rabbits	<ul style="list-style-type: none"> <li>• Leydig cell tumors,</li> <li>• Attenuates               <ol style="list-style-type: none"> <li>a) serum level of luteinizing hormone [LH],</li> <li>b) testosterone,</li> <li>c) folliclestimulating hormone,</li> <li>d) testicular strom</li> </ol> </li> </ul>	
<b>Gland/ System involved</b>	<b>Endocrine Disrupter</b>	<b>Species</b>	<b>Consequences</b>	<b>References</b>
<b>Female Reproductive System</b>	<b>MP</b>	Mice	<ul style="list-style-type: none"> <li>• Oxidative stress in ovaries,</li> <li>• Decrease the number of ovarian antral follicles</li> <li>• Reduced malondialdehyde [MDA] levels in ovaries</li> <li>• Spontaneous abortion</li> <li>• Decreased uterine blood supply</li> </ul>	[115]
	<b>MP</b>	Rats	<ul style="list-style-type: none"> <li>• Granulosa cell apoptosis,</li> <li>• Ovary fibrosis, and pyroptosis</li> </ul>	[82]
	<b>MP+ BPA</b>	Humans	<ul style="list-style-type: none"> <li>• Inhibiting secretion of progesterone and oestradiol,</li> <li>• decreases expression of CYP11A1</li> </ul>	
	<b>MP+PCBs</b>	Mice	<ul style="list-style-type: none"> <li>• Follicular atresia,</li> <li>• Suppressed level of LH, progesterone</li> </ul>	
	<b>MP+ PBDEs</b>	Humans	<ul style="list-style-type: none"> <li>• Increased menstrual cycle, bleeding time</li> </ul>	
<b>Hypothalamus</b>	<b>MP+ BPA</b>	Mice	<ul style="list-style-type: none"> <li>• Significant decrease in hypothalamic neurons,</li> <li>• Astrocyte activation</li> <li>• Impairs the function of proopiomelanocortin [POMC] neurons in the hypothalamic arcuate nucleus [ARC],</li> <li>• Astrocyte-dependent inflammation</li> </ul>	[64]
	<b>MP+ Phthalates</b>	Rats	<ul style="list-style-type: none"> <li>• Dysregulation of the HPG axis,</li> <li>• induce early puberty by upregulating hypothalamic IGF-1 expression,</li> <li>• prolong the female estrous cycle,</li> <li>• affects mRNA and protein expression of KiSS1, GPR54, and GnRH</li> </ul>	[115] [118]
	<b>MP+ PCBs</b>	Rats	<ul style="list-style-type: none"> <li>• Oxidative stress in the hypothalamus,</li> <li>• decreased hypothalamic weight,</li> <li>• decreased acetylcholinesterase (AChE) activity</li> </ul>	
	<b>MP+ PBDEs</b>	Rats	<ul style="list-style-type: none"> <li>• Dysregulation of HPT and HPG axis</li> </ul>	

Pituitary gland	MP+ Phthalates	Rats	<ul style="list-style-type: none"> <li>Altering levels of GnRH, LH, and FSH,</li> <li>increases corticosterone and ACTH levels</li> </ul>	[112] [115] [117] [118]
	MP+ PBDEs	Rats	<ul style="list-style-type: none"> <li>alter TH balance at HPT-axis,</li> <li>disrupting normal HPT-axis,</li> <li>carcinogenic effects in the pituitary of male rats and the uterus of female rats</li> </ul>	
	MP+ Mercury	Humans	<ul style="list-style-type: none"> <li>Inhibits LH and FSH secretion,</li> <li>menstruation disorders,</li> <li>Leydig cells deformation,</li> <li>impaired follicular development</li> </ul>	
	MP+ Cadmium	Rats	<ul style="list-style-type: none"> <li>Decreased circulating levels of LH and FSH</li> </ul>	
	MP+ Chromium	Rats	<ul style="list-style-type: none"> <li>Increased adrenal D53b-hydroxysteroid dehydrogenase [HSD] activity,</li> <li>Increased adrenal weight,</li> <li>serum corticosterone level increased</li> </ul>	
	MP+ Phenols	Rats	<ul style="list-style-type: none"> <li>Damages the endogenous estrogenic cascade in the adrenal gland,</li> <li>cause changes in the regions of the cortex medulla,</li> <li>Causes cytoplasmic decomposition in cells of the cortex and hemorrhage in the tissue interface</li> </ul>	
<b>Gland/ System involved</b>	<b>Endocrine Disrupter</b>	<b>Species</b>	<b>Consequences</b>	<b>References</b>
Digestive system	MP+PS	ICR mice	<ul style="list-style-type: none"> <li>Accumulate in kidneys, liver, and gut</li> <li>Energy disturbance</li> <li>Disturbance of lipid metabolism</li> <li>Oxidative stress</li> <li>Decrease amino acid in female mouse offspring but opposite in male offspring</li> <li>Change in acyl-carnitine and free carnitine</li> <li>Metabolic disorders in offspring</li> </ul>	[112] [115]
	MP+PE	Mice C57BL/6	<ul style="list-style-type: none"> <li>Inflammation</li> <li>Decrease the percentage of Th17 and Trey</li> <li>Intestinal inflammation</li> <li>Intestinal dysbacteriosis</li> </ul>	
	MP+PS MP+ Pristine PS	ICR mice	<ul style="list-style-type: none"> <li>Reduce intestinal mucus secretion</li> <li>Damage to the intestinal barrier function</li> <li>Aactinobacteria load reduced</li> <li>Metabolic disorder</li> </ul>	

			<ul style="list-style-type: none"> <li>• Alter gut microbiota</li> <li>• Increase TBA in the liver</li> <li>• Altered feeding behavior and growth rate</li> </ul>	
<b>CNS</b>	<b>MP+DBP</b>	Mice	<ul style="list-style-type: none"> <li>• Reduction protein expression levels of               <ul style="list-style-type: none"> <li>✓ Nr4a3,</li> <li>✓ Egr1,</li> <li>✓ Arc,</li> <li>✓ BDNF</li> <li>✓ AKT phosphorylation</li> </ul> </li> <li>• Decrease scores in negative geotaxis at PND 7 and swimming scores and olfactory orientation tests at PND 14</li> <li>• Increase dark neurons</li> <li>• Delay pup development</li> </ul>	[115] [118]
	<b>MP+BPA</b>	Inbred Swiss albino mice	<ul style="list-style-type: none"> <li>• Anxiety</li> <li>• Alterations in the ratio of excitatory–inhibitory proteins</li> <li>• Inhibited PSD95 expression</li> <li>• Reduce morphological changes, spine stability</li> <li>• Blocked LTP induction</li> </ul>	
	<b>MP+BPA</b>	Human Infants	<ul style="list-style-type: none"> <li>• Increase oxidative stress</li> <li>• Mitochondrial dysfunction</li> <li>• Behavior complication in patients with ASD</li> </ul>	
<b>Gland/ System involved</b>	<b>Endocrine Disrupter</b>	<b>Species</b>	<b>Consequences</b>	<b>References</b>
	<b>MP+DBP</b>	Rats	<ul style="list-style-type: none"> <li>• Changes in sensory motor development</li> <li>• Reflex response</li> <li>• Low memory retention</li> <li>• Altered cyto-architecture in hippocampus</li> <li>• Disrupt neural and endocrine functions</li> </ul>	[64]

**Declaration of interests**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Journal Pre-proof